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INTRODUCTION 
 Introduction 
CHAPTER 1 
THE HUMAN IMMUNODEFICIENCY VIRUS 
The human immunodeficiency virus (HIV) is a Retrovirus belonging to the family of 
Lentivirus. HIV is the etiologic agent of the acquired immunodeficiency syndrome (AIDS) 
that results in extremely variable clinical outcomes, such as a severe immunodeficiency 
accompanied by the establishment of opportunistic infections and tumors, organ decay 
and central nervous system degeneration [1]. Two different HIV viruses exist: HIV-1, the 
pandemic type, and HIV-2, more represented in West Africa [2]. 
 
1.1 STRUCTURE AND GENOME 
HIV has a spherical form with an external lipoproteic envelope and an internal 
nucleocapside called core. The envelope is formed by a double phospholipid layer of host-
cell origin in which the viral glycoproteins gp120 and gp41 are embedded. Gp120 and 
gp41 originate from the proteolitic cleavage of the gp160 precursor encoded by the env 
gene, they are exposed on the envelope in a trimeric form and control viral tropism by 
mediating the fusion of the virus membrane with the target cell. The core is made by p24 
proteins and it encloses HIV genome, and virus-specific enzymes like reverse 
transcriptase, integrase and protease. The integrity of virion particle is ensured by the viral 
protein p17, which forms the matrix and surrounds the internal core (fig.1). 
 
 
Figure 1. Human Immunodeficiency Virus type-1 (HIV-1): section of the structure of the 
virion.  
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HIV genome (fig.2) is composed by two identical copies of positive-sense single-stranded 
RNA (ssRNA+), each 9.2kb long, associated with two nucleocapside proteins (p7 and p9). 
HIV genome shows the typical genomic organization of virus belonging to Retroviridae 
family. It encodes for structural genes (gag, pol and env), regulator genes (tat, rev, nef, 
vpr, vpu and vif) and regulator sequences. Gag encodes for nucleocapsid and matrix 
proteins, pol for reverse transcriptase, integrase and protease while env for gp160 
glycoprotein, this is a precursor from which gp120 and gp41 proteins derive [3]. A peculiar 
characteristic of HIV consists in its capability to create overlapping transcripts, to operate 
alternative splicing and to produce polyproteins which are subsequently split into different 
functional proteins.  
At each end of the ssRNA molecule there is a sequence called Long Terminal Repeat 
(LTR) that mediates the integration of HIV genome into the genome of a host cell and 
regulates viral replication. The LTRs contain promoters and enhancers of gene 
transcription specific for host transcription factors such as Nuclear Factor kappa B (NF-
kB), activator protein 1 (AP1), nuclear factor of activated T cells (NFAT), as well as virus-
encoded factors [4] 
 
 
 
 
Figure 2.Organization of the HIV-1 genome. 
(From Haseltine W.A., “Molecular biology of human immunodeficiency virus type 1”, The FASEB 
Journal, Vol. 5, no. 10, 1991, pp. 2349-2360). 
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1.1.1 The viral envelope 
The HIV envelope is a phospholipid bilayer acquired from the host cell during virion 
budding and release. The envelope contains host-derived proteins, including Human 
leukocyte antigens (HLAs) and adhesion molecules, and a series of spikes of 9-10 nm in 
length, called Env. Each spike is a trimeric complex of a glycoprotein of 120 kDa, called 
gp120 that from a cap non-covalently bound to a stem of a trimeric complex of 
transmembrane glycoprotein of 41 kDa, called gp41. The env gene encodes a protein 
called gp160 that, after glycosylation in the Golgi apparatus, is cleaved into gp120 and 
gp41. Respectively, these proteins enable HIV to attach to and fuse with the target cell 
membrane [5, 6]. 
 
1.1.2 The viral core 
The core of HIV is a nucleocapsid made of an elongated conical shell with icosahedral 
symmetry composed of proteins of 24 kDa in weight, called p24, which contains the HIV 
genome. The nucleocapsid is surrounded by a spherical shell, known as matrix, made of 
proteins of 17 kDa, called p17, anchored to the viral envelope through a myristic acid 
residue. The two ssRNA+ molecules in the capsid are associated with two proteins of 7 
and 9 kDa, called p7 and p9 respectively that function as packaging proteins. The proteins 
p7, p9, p17 and p24 are encoded by the gene gag, which transcript is translated in a poly-
protein of 55 kDa, called p55 that is then cleaved by viral proteases in the above 
mentioned components during virion maturation [7]. In addition to the ribonucleoproteic 
complex, the core contains several virus-encoded enzymes: the reverse transcriptase 
(RT), a heterodimer constituted of two proteins of 66 and 51 kDa, the integrase, called p32 
that facilitates the insertion of HIV genome into the host genome, and the protease, a 
homodimer composed of a protein of 10 kDa. These enzymes are encoded by the gene 
pol, which transcript is translated into a poly-protein of 180 kDa, called Gag-Pol, that is 
then cleaved by the viral potease itself [8]. The core also contains molecules that are 
important for the early stages of the biologic cycle of HIV and accessory proteins. Some of 
these proteins are virus-encoded such as Trans-activator of transcription (Tat or p14), 
Regulator of virion expression (Rev or p19), Negative regulatory factor (Nef or p27), Viral 
infectivity factor (Vif or p23), Viral protein U (vpu or p16) and Viral protein R (Vpr or p15) 
(or Viral protein X in case of HIV-2), and some derive from the host cell, such as 
cyclophilin A and a tRNAlys that serves as primer for the RT to initiate HIV genome reverse 
transcription [9]. 
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1.2 TROPISM 
The term viral tropism refers to which cell types HIV infects. HIV can infect a variety of 
immune cells such as CD4+ T cells, macrophages, and microglial cells. HIV-1 entry to 
macrophages and CD4+ T cells is mediated through interaction of the virion envelope 
glycoproteins (gp120) with the CD4 molecule on the target cells and also with chemokine 
coreceptors [10]. 
Macrophage (M-tropic) strains of HIV-1, or non-syncitia-inducing strains (NSI) use the β-
chemokine receptor CCR5 for entry and are, thus, able to replicate in macrophages and 
CD4+ T cells [11]. This CCR5 coreceptor is used by almost all primary HIV-1 isolates 
regardless of viral genetic subtype. Indeed, macrophages play a key role in several critical 
aspects of HIV infection. They appear to be the first cells infected by HIV and perhaps the 
source of HIV production when CD4+ cells become depleted in the patient. Macrophages 
and microglial cells are the cells infected by HIV in the central nervous system. In tonsils 
and adenoids of HIV-infected patients, macrophages fuse into multinucleated giant cells 
that produce huge amounts of virus. 
T-tropic isolates, or syncitia-inducing (SI) strains replicate in primary CD4+ T cells as well 
as in macrophages and use the α-chemokine receptor, CXCR4, for entry [11, 12, 13]. 
Dual-tropic HIV-1 strains are thought to be transitional strains of HIV-1 and thus are able to 
use both CCR5 and CXCR4 as co-receptors for viral entry. 
The α-chemokine SDF-1, a ligand for CXCR4, suppresses replication of T-tropic HIV-1 
isolates. It does this by down-regulating the expression of CXCR4 on the surface of these 
cells. HIV that use only the CCR5 receptor are termed R5; those that use only CXCR4 are 
termed X4, and those that use both, X4R5. However, the use of coreceptor alone does not 
explain viral tropism, as not all R5 viruses are able to use CCR5 on macrophages for a 
productive infection [11] and HIV can also infect a subtype of myeloid dendritic cells, [14] 
which probably constitute a reservoir that maintains infection when CD4+ T cell numbers 
have declined to extremely low levels. 
Some people are resistant to certain strains of HIV [15]. For example, people with the 
CCR5-Δ32 mutation are resistant to infection with R5 virus, as the mutation stops HIV from 
binding to this coreceptor, reducing its ability to infect target cells. 
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Sexual intercourse is the major mode of HIV transmission. Both X4 and R5 HIV are 
present in the seminal fluid, which is passed from a male to his sexual partner. The virions 
can then infect numerous cellular targets and disseminate into the whole organism. 
However, a selection process leads to a predominant transmission of the R5 virus through 
this pathway [16, 17 and 18]. How this selective process works is still under investigation, 
but one model is that spermatozoa may selectively carry R5 HIV as they possess both 
CCR3 and CCR5 but not CXCR4 on their surface [19] and that genital epithelial cells 
preferentially sequester X4 virus [20]. In patients infected with subtype B HIV-1, there is 
often a co-receptor switch in late-stage disease and T-tropic variants appear that can 
infect a variety of T cells through CXCR4 [21]. These variants then replicate more 
aggressively with heightened virulence that causes rapid T cell depletion, immune system 
collapse, and opportunistic infections that mark the advent of AIDS [22]. Thus, during the 
course of infection, viral adaptation to the use of CXCR4 instead of CCR5 may be a key 
step in the progression to AIDS. A number of studies with subtype B-infected individuals 
have determined that between 40 and 50 percent of AIDS patients can harbor viruses of 
the SI and, it is presumed, the X4 phenotypes [23, 24]. 
 
1.3 REPLICATIVE CYCLE OF HIV-1  
 
HIV begins its life cycle when the viral glycoproteins gp120/gp41 (ENV complex) bind to a 
CD4 receptor and one of two co-receptors on the surface of a target cell (fig.3). 
Physiologically HIV-1 co-receptors belong to chemokine receptor family the most important 
of which are CCR5 and CXCR4. CCR5 is typically expressed on macrophages therefore 
viral strains that exploit it are named M-tropic strains, conversely CXCR4 is mainly 
expressed on T cells and virus strains that use it are known as T-tropic strain.  
The Env complex mediates a multistep fusion process. Gp120 binds to CD4 receptor and 
subsequently to the chemokine coreceptor, allowing gp41 to change its conformation and 
to expose a hydrophobic region called fusion peptide; this peptide inserts into the cell 
membrane and allows the fusion between the target cell membrane and the viral 
membrane.  
After the fusion, the nucleoprotein core is disrupted; reverse transcriptase transcribes 
genomic RNA in double strand DNA which enters into the nucleus together with the 
integrase enzyme. Integrase promotes the integration of viral DNA in the cellular genome. 
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The integrated viral DNA is called provirus and it can be latently inactive for long periods of 
time without being transcribed.  
 
Figure 3. Schematic representation of HIV entry into CD4+ cell via 
CCR5 co-receptor. 
 
Transcription of the provirus genes is regulated by the LTR sequences. LTR are regulator 
sequences at the ends of HIV genome which form during retrotranscription of RNA in 
proviral DNA; they are important because they contain polyadenylation signal sequences, 
the TATA box promoter sequence and binding sites for two host cell transcription factors, 
NF-κB and AP1 which regulate the provirus transcription following the interaction with viral 
and host factors. Initiation of HIV gene transcription in T-cells can be initiated only after T-
cell activation induced by antigen presentation or cytokine action. HIV genes expression 
can be divided in an early and late phase. Regulator genes (tat, rev, nef) are transcribed in 
the early phase of HIV life cycle, in a full-length transcript which is spliced and translocated 
from nucleus to cytoplasm to be translated in proteins. Rev promotes nuclear export of 
incompletely spliced and unspliced viral mRNAs. Tat is required for elongation of viral 
transcripts by direct binding to mRNA and by increasing the processivity of host RNA-
polymerase. Moreover Tat can be secreted by infected cells, as a matter of fact, its 
concentration is consistent in sera of HIV-infected and extracellular Tat can act as a viral 
toxin triggering T cell apoptosis and the secretion of many cytokines by monocytes 
contributing to immune dysfunction and progression of HIV disease.  
Nef plays a pivotal role in accelerating endocytosis and degradation of CD4 and MHCI 
host cell molecules other than enhancing the release of virus from infected cells. The role 
played by Vif, Vpr and Vpu: in viral replication is not completely clarified. Vif enhances 
infectivity of viral particles, Vpr promotes nuclear import of viral DNA and Vpu plays a 
similar role to that played by nef and also promotes maturation and trafficking of gp160 
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protein.The switch from early gene to late gene is regulated by Rev, which allows the 
translocation of unspliced late genes to the cytoplasm.  
As previously mentioned late genes (pol, gag and env), are synthesized as precursor 
protein and are subsequently cleaved. Pol gene encodes for reverse transcriptase, 
protease, ribonuclease and integrase protein. Gag encodes for a precursor protein that it is 
subsequently cleaved in p24, p17 and p15 by pol protease, these are core proteins, 
necessary for assembly of viral particles. Env gene encodes for gp160, precursor of gp120 
and gp41.   
Assembly of viral particles begins by packaging full-length RNA transcripts of the proviral 
genome with proteins encoded by gag genes and pol enzymes. Viral particles are released 
from the target cell through a process of budding and in this passage they acquire the 
phospholipid layer and expose gp120 and gp41 proteins on viral particles surface (fig.4). 
[25].  
Figure 4. Mechanism of action of HIV-1 virus 
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CHAPTER 2:   
 
NATURAL HISTORY OF HIV INFECTION 
 
2.1 PATHOGENESIS of HIV-1 INFECTION 
 
The pathogenesis of HIV-1 infection begins as an acute infection that after a long period of 
latency, which can last 3 to 20 years, leads to a severe status of immunodeficiency, called 
acquired immunodeficiency syndrome (AIDS) [26]. The major determinant of the 
pathogenesis and disease caused by HIV-1 is the virus tropism for CD4+ T cells, which 
results in a reduction in the number of these cells and consequent abolition of the helper 
function of adaptive immunity. HIV-1 induces several cytopathology effects that may kill 
the infected T cell. In the acute phase of infection, HIV-induced cell lysis and killing of 
infected cells by CTLs account for CD4+ T cell depletion, although apoptosis may also be 
an important factor [27]. During the chronic phase, the consequences of generalized 
immune activation, coupled with the gradual loss of the ability of the immune system to 
generate new T cells, account for the slow decline in CD4+ T cell number [28,29]. 
The course of HIV disease parallels the reduction in CD4+ T cell numbers and the amount 
of virus in the blood (Fig. 5). During the acute phase, there is a large burst of virus 
production and infection spread systemically, in particular to secondary lymphoid organs. T 
cell proliferation and responses to the infected lymphoid and myeloid cells promotes a 
mononucleosis-like syndrome. The CD8+ T cell response is thought to be important in 
controlling virus levels, which peak and then decline, as the CD4+ T cell counts recover. 
Virus levels in the blood decrease during a clinically latent period, but viral replication 
continues in the secondary lymphoid organs [31]. At the same time, virus can remain latent 
in macrophages, dendritic cells and resting T cells, establishing reservoirs in many organs. 
Continuous HIV-1 replication results in a state of generalized immune activation persisting 
throughout the chronic phase [28]. Immune activation, which is reflected by the increased 
activation state of immune cells and release of pro-inflammatory cytokines, results from 
the activity of several HIV-1 gene products and the immune response to ongoing HIV-1 
and co-infecting pathogen replication. Immune activation has also been linked to the 
breakdown of the defenses of the gastrointestinal mucosal barrier caused by the depletion 
of mucosal CD4+ T cells during the acute phase of disease [32, 33]. 
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Figure 5. Time course and stages of HIV disease. 
 
Late in the disease, virus levels in the blood increase, CD4+ levels are significantly 
decreased, CD8+ levels also decrease, X4-tropic virus rises (in about 50% of the infected 
individuals), the structure of the lymph nodes is destroyed [34], and the patient becomes 
immunosuppressed (Fig 5). Stage IV or AIDS, as defined by the World Health 
Organization, is characterized by severe symptoms which includes toxoplasmosis of the 
brain, candidiasis of the esophagus, trachea, bronchi or lungs and Kaposi's sarcoma, and 
a CD4+ T cell count of less than 200/L [35].  
The central role of the CD4+ helper T cells in the initiation of an adaptive immune response 
is indicated by the extent of the loss of function caused by HIV-1 infection. When CD4+ T 
cells are unavailable or not functional, antigen-specific immune responses (especially 
cellular immune responses) are incapacitated, and humoral responses are uncontrolled. 
The loss of the CD4+ T cells responsible for activating macrophages allows the outgrowth 
of many of the opportunistic intracellular infections characteristic of AIDS (e.g., fungi and 
intracellular bacteria). Of importance, the decrease in number and the inability to activate 
CD8+ T cells increases the potential for recurrence of latent viruses, including JC 
polyomavirus progressive multifocal leukoencephalopathy (PML), herpes simplex virus, 
and cytomegalovirus infections, and even Epstein-Barr-associated lymphomas and human 
herpesvirus-8-associated Kaposi sarcoma [30].  
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2.2 CLINICAL COURSE OF DISEASE PROGRESSION: 
 
A typical characteristic of HIV-1 infection is the huge variability of the progression of the 
disease in the infected patients. Based on the duration of the HIV-1 infection and on the 
kinetic of the virologic and immunologic events observed during the disease, the clinical 
course of disease progression can be divided into three phases: 60-70% of HIV-1 infected 
people are “Typical Progressors” and the median time from infection to development of 
AIDS is approximately 10 years; 10-20% of HIV-1 infected people are “Rapid Progressors” 
and they progress rapidly to AIDS within 5 years; 5-10% of people infected showed no 
clinical progression for several years (10-15) and they are called “Slow Progressors” (SP) 
and they maintain a stable CD4+ count ≥ 500 cell/ul with plasma viremia ≤ 10.000 
copie/ml. To this category belongs also a subgroup of 2-3% of infected people called “long 
term non-progressors” LTNP, (36), fig 6. 
 
 
 
Figura 6. Plasma viremia variation, lymphocytes T-CD4+ count and 
immune response in 4 stages of the disease. 
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More recently, a subset of infected individuals, called Elite Controllers, with spontaneous 
and sustained control of HIV infection, with viral loads <50 RNA copies/ml in the absence 
of therapy have been described [37, 38],(tab.1). This spontaneous control occurs in 
approximately 1 in 300 HIV-infected persons, and the HIV Controller Consortium was 
recently established to study host genetics together with functional immunology studies in 
elite controllers. 
 
 
 
 
EC 
 
LTNP 
CD4+ t-cell level (cell/ ul) ≥500* 
 
≥500 
viral load (copies/ml) ≤50 
 
≤10000 
antiretroviral therapy No 
 
No 
Years without AIDS 
Months-
years  
≥7-20* 
                 
*values can vary in studies   
 
 
Table 1. Definitions of major controller populations 
 
 
 
Interest in non-progressive HIV-1 infection has increased over time in the hope of 
understanding HIV pathogenesis and the mechanisms of protection involved, and 
providing insights relevant to viral attenuation, novel therapies and vaccine design [38]. SP 
or LTNP cohorts provide a unique opportunity to study the complexity of the virus-host 
interaction with the aim of understanding the biological and molecular correlates of 
protection against HIV-1 infection and disease progression. The duration of clinical latency 
following HIV-1 infection is regulated by the interplay of at least three virus-host factors: (i) 
genetic susceptibility of the host, (ii) the hosts’ ability to mount an effective immune 
response, and (iii) the genotypic properties of the infecting viral quasispecies [39, 40]. 
 
 
2.3 LONG TERM NON PROGRESSORS (LTNP) 
 
2.3.1 Definition 
 
Infectious diseases can be extremely variable in their clinical manifestations. In the case of 
HIV, the time from infection to the development of AIDS varies widely. Typically, the 
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median time from infection to AIDS is estimated to be 10 years [41, 42] with peripheral 
CD4+ T lymphocytes typically declining at a rate of 50-90 cells/mm3/year [43,44,45]. 
Although rapid progression is rare, there have been reports describing progression to 
AIDS within 2-4 months after primary infection [46,47] and within 2 years in infants infected 
by blood transfusions [48]. At the other extreme, investigators have also identified 
untreated HIV-1 infected individuals who remain healthy and AIDS free for more than 13 
years [49]. 
 
In the HIV-infected population, the proportion of individuals classified as long term non 
progressors (LTNP) varies widely due to differences in study design, the length of 
available follow-up and inconsistency in the criteria's used to define LTNP. In the 
Tricontinental and Italian Seroconverted Study, five definitions were used to categorize 
LTNP. They found that the proportions of LTNP varied from 0.5 – 25 % depending on the 
defining criteria such as time to AIDS, CD4 count thresholds and use of ARVs [50, 51, 52]. 
There is evidence today of yet another category of potentially slow progressing HIV 
infected individuals. A criterion incorporating viral load (VL) measures found that 
approximately 1 patient in 300, naive to ARV therapy, has undetectable viremia below the 
detection threshold of 50 RNA copies/ml (Elite HIV controllers or EC). EC must be infected 
for at least one year and unlike typical LTNP definitions, CD4 counts are not always 
considered [53-56]. In contrast, a typical LTNP definition requires that CD4 counts be 
above 500 cells/mm after at least 7 years of untreated infection [57]. This definition is 
supported by the observation that in untreated HIV infection, the median time for CD4+ T 
cell counts to fall below 500 cells/mm3 is 1.7 yrs (95% confidence intervals 1.29 to 1.89 
yrs) [58]. Additionally, while untreated HIV disease progressors have a declining peripheral 
CD4 count of approximately 50-90 cells/mm3/year, LTNPs loose on average 6 cells/mm 
/year, a rate not significantly different from that seen in HIV seronegative controls [45,59]. 
It is commonly accepted that LTNPs represent the tail end of a continuous distribution of 
progression rates and that individuals who never progress to AIDS are extremely rare [57-
60]. The findings that LTNPs are not a discrete homogenous group could be seen as a 
study population devoid of relevant information on mechanisms of disease progression. 
However, it has become clear over the years that multiple virologic, genetic and 
immunologic factors influence the rate of disease progression. Studying factors that impact 
on the natural course of HIV is crucial to the rational design of therapeutic vaccines. 
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Translating this knowledge into novel therapies will hopefully prolong the life of infected 
individuals and reduce the rate of HIV transmission. 
 
2.3.2 Demographic cofactors of progression 
 
Psychological, behavioral and environmental factors can potentially alter the natural 
history of HIV infection. LTNP have been identified in all HIV-infected risk groups: 
heterosexuals, MSM, IDU, transfusion recipients and perinatally-acquired infections [61]. 
Studies of LTNP have not found a significant association between age and rates of 
disease progression. However, older age at seroconversion is one factor that is associated 
with more rapid progression to AIDS and death [62]. The extrapolated median time to 
AIDS for a person infected at age 20 is 10.2 years and for a person infected at age 40 is 
7.4 years [63-65]. The overall evidence for epidemiologically linked cofactors such as 
geographical location (ethnicity), route of transmission, social status or lifestyle cofactors 
has not shown strong correlations with delayed AIDS progression [66-69]. 
 
2.3.3 Virologic cofactors of progression 
 
A number of viral factors have been recognized to influence disease progression. Unlike 
typically progressing individuals, LTNP are reported to have lower VL, proviral DNA and 
multiply spliced RNA. These observations are consistent with a large number of published 
reports which suggest that the rate of disease progression is driven by viremia and 
immune activation. Individual case reports or small patient cohort studies have described 
infections with attenuated forms of HIV-1 leading to decelerated disease progression. Viral 
polymorphisms associated with LTNP status have been identified in the non-coding LTR 
region and in structural, regulatory and accessory genes. Kestler et al. first demonstrated 
that Nef-defective SIV causes attenuated disease in primates. Nef is required for 
maintaining viral replication and pathology during the course of persistent infection in 
rhesus monkeys. Subsequent studies confirmed the relationship between Nef and disease 
progression in a murine model of HIV. In humans, the best known example of Nef-
attenuated virions is provided by the Sydney Blood Bank Cohort (SBBC). The cohort 
consisted of 8 individuals inadvertently transfused with an attenuated HIV strain lacking a 
functional Nef gene. All except one recipient and the donor remained clinically free of 
symptoms, with stable and normal CD4+ T cell counts 10 to 14 years after infection. 
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Genetic analysis of sequences from virus isolates and peripheral blood mononuclear cells 
(PBMC) revealed a 29 base-pair deletion in the Nef gene and in the overlapping region of 
Nef and LTR. Nef has multiple functions responsible for pathogenesis and immune 
evasion. These include the downregulation of CD4, MHC class I and CD28. Nef is also 
described to mediate cellular signalling, activation and enhancement of virus infectivity. 
Investigators show that LTNPs harboring Nef/LTR deletion mutants have low levels of 
immune activation and strong HIV-specific proliferative responses. However, follow up 
information documented immunological damage and progression in 3 individuals 
suggesting that although they experienced a delay in disease progression, infection with 
attenuated viral quasispecies is not completely protective. 
Accounting for a small proportion of cases of non-progression, mutations within Gag pl, 
LTR and accessory genes (Vif, Vpr, Vpu, Tat and Rev) have been associated with slow 
HIV disease progression. Changes in Env that affect viral tropism are also important 
modulators of HIV-1 disease progression. A switch in the specificity of HIV-1 Env from R5 
to X4 or R5X4 is considered an indicator of poor prognosis, partly because it increases the 
number of CD4 cells that are susceptible to cytolytic infection by HIV-1. Although some 
studies have indicated that LTNP and EC harbor slow replicating defective viruses, these 
findings do not account for slow disease progression in most individuals experiencing a 
benign course of disease. A recent study described the transmission of HIV-1 from a LTNP 
to two individuals that subsequently developed progressive disease. This indicated that 
host characteristics are important determinants of non-progression.  
 
2.3.4 Host genetic cofactors of progression. 
 
Host genetic factors associated with disease progression have focused on HLA genes, as 
discussed in a previous section, but also on chemokine coreceptors, their ligands and 
cytokines. While a 32-base-pair deletion in the CCR5 chemokine receptor gene is 
associated with resistance to HIV infection60, heterozygous individuals for the CCR5A32 
deletion exhibit slower disease progression taking 2 to 4 years longer to develop AIDS. 
This is caused by a lower expression of surface CCR5 coreceptors which translates into 
slower HIV-1 replication and reduced pathogenesis. The association between CCR5 
genotype and rate of disease progression however is modest and the effect of CCR5 
genotype on disease can vary in different risk groups or at different stages of infection. In 
addition, the protective effect exerted by CCR5 heterozygosity accounts for no more than 
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one third of LTNPs. Single nucleotide polymorphisms (SNP) in the CCR5 promoter region 
appear to influence progression. The CCR5 PI haplotype comprising 13 distinct SNP 
upstream of the promoter confer rapid disease progression by influencing CCR5 
abundance on lymphoid cells. A Valine to Isoleucine mutation at position 64 (V64I) of 
CCR2 mediates delay in AIDS progression indirectly as it causes no allele-specific 
quantitative difference in the amount of CCR2 produced. The variant CCR2 protein 
preferentially heterodimerizes with CXCR4 polypeptides reducing expression and delaying 
disease progression. 
RANTES is the principal chemokine ligand for CCR5. Elevated circulating levels of 
RANTES have been detected in individuals who have a delayed onset of AIDS. 
Conversely, SNP in an intronic regulatory sequence downregulates RANTES production 
by a factor of 4 leading to rapid progression. Polymorphisms at the 5' promoter region of 
IL-10 and IFN-y have been implicated in modulating disease progression. The IL-10 SNP 
variant reduces IL-10 transcription by a factor of 2-4. Heterozygous and homozygous 
individuals experience an accelerated course of disease presumably caused by a 
heightened state of immune activation446. Individuals heterozygous for a functional 
polymorphism identified in the IFN-y promoter progress to AIDS more rapidly. This SNP 
(G-179T) represents a Guanidine to Thymidine transition and confers TNF-a inducibility. It 
is hypothesized that increased IFN-y production induced by TNF-a causes CD4 cell 
depletion by apoptosis. 
Using a genome-wide association strategy, researchers identified polymorphisms that 
account for 15% of the variability in the viral load set point during the asymptomatic period. 
Among them, HLA complex P5 (HCP5) is found within an endogenous retroviral element 
and is in high linkage disequilibrium with HLA-B*5701 while the second SNP is located in 
the 5' region of the HLA-C gene. A third polymorphism encoding an RNA polymerase 
subunit contributed to 5.8% of the variation in the rate of disease progression.  
Given the importance of the gut in the pathogenesis of HIV, investigators evaluated gene 
expression profiles in intestinal biopsies sampled from LTNPs. A significant increase in 
mucosal gene expression regulating immune activation and inflammation was detected in 
high VL patients compared to LTNPs. However both groups showed deregulation in genes 
associated with cell cycle regulation, lipid metabolism and enterocyte function. 
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2.3.5 Immunologic cofactors of progression 
 
NAbs directed against HIV-1 have the potential to play an important role in preventing viral 
infections both in vitro and in animal models [70-72]. With the help of cellular immune 
responses, evidence suggests that Nab potentially prevent or delay the progression to 
AIDS. Studies have shown that Nabs induced by infection or passively transferred 
contribute to controlling viral replication [73,74] and are more avid and more abundant in 
LTNP than in other HIV-infected individuals [75-76]. However other reports failed to detect 
effective NAb responses in LTNPs suggesting that their contribution in the prevention of 
disease progression remains unclear Immune pressure mediated by NAb induces rapid 
escape variants and studies have shown their protective effects only when present at high 
doses [74]. 
Both innate and adaptive immune responses potentially contribute to the initial 
containment of infection and hence may be crucial in modulating the subsequent course of 
disease. DCs are the most potent antigen-presenting cells involved in the generation of 
both innate and acquired immune responses464'465. Data suggests they are impaired in 
number and function in HIV-infected individuals. Several studies have reported a reduction 
in the number of blood myeloid dendritic cells DC (mDC), plasmacytoid dendritic cells 
(pDC) and tissue Langerhans cells (LC) in HIV-infected progressors. LTNPs maintain their 
pDC numbers suggesting that control of viremia is mediated by the secretion of large 
amounts of IFN-a. In addition, mDC and pDC isolated from progressing patients showed 
an impaired ability to stimulate allogeneic T cell proliferation [75]. 
Natural Killer cells (NK) exert their antiviral effect both by direct killing of infected cells and 
by secretion of cytokines and chemokines which help direct the adaptive arm of the 
immune response. Supernatants from NK cell cultures were found to suppress 
endogenous HIV replication in autologous CD4+ T cells by secreting CC chemokines such 
as RANTES, MlP-1 alpha and MIP-1 beta. NK cells may also lyse infected targets through 
the secretion of perforin, granzyme and by ADCC. A previous study found a genetic 
association between an activating NK cell receptor KIR3DS1 and delayed progression to 
AIDS when coexpressed with HLA-B molecules expressing an Isoleucine at position 80. 
Functional and phenotypical differences have also been observed between NK cells 
isolated from LTNP and progressors. Both natural killer cytotoxicity receptors and cytotoxic 
activity were found to be decreased in viremic compared to LTNP individuals [76]. 
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Regulatory T cells (Tregs) are a subset of CD4+ lymphocytes that limit the expansion and 
activation of autoreactive T cells effectively preventing autoimmune disease. The role 
Tregs play in the pathogenesis of HIV is still controversial. On the one hand, a decrease in 
circulating Tregs has been reported in the periphery of chronically infected individuals 
potentially through direct infection and killing. These findings support the view that lack of 
immunosuppresion favors immune activation and disease progression. On the other hand, 
the expression of Treg markers was found to be increased in the tonsils of HIV-infected 
individuals suggesting that altered trafficking or accumulation of Tregs in lymphoid tissues 
is responsible for their decreased frequency in the periphery. 
Although an accumulation of Tregs at sites of viral replication can limit the damage caused 
by hyperactive immune responses, it has been hypothesized that it can also prevent the 
development of a protective adaptive immune response. In support of this view, LTNPs 
have low numbers of Tregs at multiple lymphoid sites suggesting that Tregs prevent the 
mounting of efficient HIV-specific immune responses in progressing individuals. A critical 
balance between positive and negative signals is crucial for effective immunity. 
Suppression may limit protective HIV-specific immune responses but it can also contain 
viral replication by inhibiting CD4+ T cell activation and infection. Several additional 
immunological differences exist between LTNPs and progressors. 
LTNPs appear to exhibit a balanced Thl/Th2 response with increased expression of IL-2, 
IFN-y, IL-4 and IL-10 production. LTNP maintain higher proportions of end stage CD8+ 
(CD45RA+CCR7"CD62L") effector cells and mount potent HIV-specific CD4+ and CD8 
proliferative responses with the capacity to produce larger quantities of perforin [77]. 
 
2.3.6 Co-infections. 
 
Human co-infection of HIV-1 with other viruses such as Human T-cell lymphotropic Virus, 
Herpes simplex virus type 2 [78], Varicella zoster virus (Hung et al., 2005) and 
cytomegalovirus (Saillour et al., 1998) are associated with an increased rate of disease 
progression to AIDS. Interestingly, infections with helminths shift the immune response 
from Th1 response to a less protective Th0/2 type response (reviewed in [79]). It appears 
that the aforementioned infections result in a more rapid progression to AIDS. Similarly, 
malaria has been associated with increases in HIV-1 viral load that may impact HIV 
progression in coinfected individuals (reviewed in [80]). 
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By contrast, coinfection with GBV-C (hepatitis G virus) has been shown to result in a lower 
mean viral load and a higher mean CD4 cell count and subsequent retardation of disease 
progression. The latter findings have however, been disputed although these effects may 
be only noted in advanced HIV infection. 
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CHAPTER 3: TRL9 AND IMMUNITY TO INFECTIOUS DISEASE  
 
3.1 TLR IN THE IMMUNE SYSTEM 
 
TLRs play an important role in innate immune recognition; they are the first line of innate 
defense against microorganisms. TLRs belong to the family of pattern recognition 
receptors (PRR) due to their ability to recognize pathogen conserved structures, known as 
pathogen-associated molecular patterns (PAMPs). PRRs are expressed mainly by 
macrophages, dendritic cells, endothelial cells mucosal epithelial cells and lymphocytes; 
they can be localized at intracellular level or on the surface of these cellular populations. 
Other receptors are involved in innate recognition but TLRs have been studied most 
extensively, to date 13 receptors (TLR1-TLR13) have been described. They are distinct on 
the base of their cellular localization and their specific ability in PAMPs recognition.   
TLR-1, -2, -4, -5, -6 are expressed on cell surface and they are mainly involved in 
detecting microbial products while TLR-3, -7, -8, -9 are localized on late endosome-
lysosome vesicles and do recognize nucleic acid of both viral and bacterial origin. So far, 
TLR-10, -11, -12, -13 are orphan receptors and less is known about them.  
All the TLRs show the same structural organization, they are type I integral membrane 
glycoproteins characterized, at the extracellular side by leucine-rich regions responsible for 
the recognition of pathogens and at the transmembrane and cytoplasmic level by 
Toll/interleukin-1 receptor (TIR) domain. Signal transduction is activated only after TLRs 
dimerization because this allows the binding of adaptor proteins like MyD88 or TIR-domain 
containing adapter inducing IFNβ (TRIF). Recruitment of MyD88 leads to the activation of 
MyD88 dependent pathway while the binding of TIR domain with TRIF induces the 
activation of the MyD88 independent pathway. All of the TLRs, except for TLR3 and in 
some cases also TLR4, bind MyD88 adaptor protein. 
 
3.2 MyD88 dependent and independent pathways  
 
After recognition of a pathogen-specific molecular pattern, TLRs are capable of 
differentially activating distinct downstream signaling events via different cofactors and 
adaptor proteins mediating diverse immune responses (fig.7).  
MyD88-dependent pathway culminates in the activation of NF-κB and JNK transcription 
factors. This pathway is activated via the conserved, cytoplasmic TIR domain, which 
provides a scaffold for recruitment of the adaptor molecule MyD88 and serine/threonine 
 Introduction 
kinases of the IL-1R-associated kinase (IRAK) family. Four IRAK have been identified: 
IRAK-1, IRAK-2, IRAK-4 and IRAK-M. IRAK-1 and IRAK-4 possess intrinsic 
serine/threonine protein kinase activities, IRAK-2 and IRAK-M lack this activity, suggesting 
that they negatively regulate TLR-mediated signaling. IRAK1 and IRAK4 are sequentially 
phosporilated and dissociated from MyD88, which results in activation of tumor necrosis 
factor receptor-associated factor 6 (TRAF6). The TRAF6 adaptor protein activates 
transforming growth factor-β-activated protein kinase 1 (TAK1) which in turn triggers the 
IKK complex that leads to the transcription factor NF-κB activation. 
 
 
 
Figure 7. TLR signaling pathway. MyD88-dependent and independent pathways are illustrated.  
 
TAK1 simultaneously phosporilates two members of the MAP kinase kinase family (such 
as JNK) which in turn activate AP-1. NF-κB and AP-1 promote the transcription of genes 
codifying macrophage inflammatory mediators, inducing B cell proliferation and endotoxin 
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shock. Experiments conducted in mice elucidated that this pathway is essential for TLR-
mediated inflammatory responses.  
MyD88-independent pathway activation is based on IFN-regulatory factor 3 (IRF-3) activity 
a transcription factor that promotes IFNβ synthesis. Recently, it has been discovered that 
IRF-3 is associated with IκB kinases (IKKs). IKKs are composed of IKKα and IKKβ, both of 
which phosphorylate IκBα thereby inducing NF-κB activation. In addition, there are two 
noncanonical IKKs, TANK-binding kinase 1 (TBK1) and IKKε/IKKi, which have distinct 
kinase activities compared with the canonical IKKα and IKKβ and both of them are able to 
promote the phosporilation of IRF-3.  
This signaling pathway could also be activated via the TIR-domain-containing adaptor 
protein (TIRAP; also designated Mal for “MyD88-adapter-like‟) and results in activation of 
the dsRNA-binding protein kinase PKR. This protein has been proposed to be a central 
downstream component of both the TIRAP- and MyD88-dependent signaling pathways 
and could mediate potential crosstalk between them. The MyD88-independent pathway 
appears to utilize both IRF3 and NF-κB, and results in the expression of IFN-inducible 
genes including IP-10.  
It has been demonstrated that NF-κB can be induced in a later phase thanks to the 
activation of IRF-3. Moreover TLR4 activation might lead to the induction of both MyD88-
dependent and -independent pathway, according to the adaptor protein that is recruited to 
the TIR domain of the receptor. Adaptor protein TIRAP promotes the activation of the 
MyD88-dependent pathway while TRIF is the inducer of the independent one [81, 82, 83].  
Following HIV infection, TLR2, TLR4, TLR7 and TLR8 are triggered. TLR2 binds to 
peptidoglycan and bacterial lipoprotein, TLR4 recognizes LPS, TLR7 and TLR8 bind to 
ssRNA.  
Moreover experimental evidences show that TLRs expression is not restricted to APC but 
they characterize other cellular population like T regulatory cells (Tregs). 
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Figure 8. TLRs and their ligands. TLR1–TLR7 and TLR9 have been characterized to recognize 
microbial components. TLR2 is essential for the recognition of microbial lipopeptides. TLR1 and TLR6 
associate with TLR2, and discriminate subtle differences between triacyl- and diacyl lipopeptides, 
respectively.TLR4 recognizes LPS. TLR9 is the CpG DNA receptor, whereas TLR3 is implicated in 
the recognition of viral dsRNA. TLR5 is a receptor for flagellin. Thus, the TLR family discriminates 
between specific patterns of microbial components 
 
 
TLR9  
TLR9 is localized in the intracellular endolysosomal compartment, it’s activated by 
unmethylated CpG motifs within single strand DNA that are present in bacteria and 
viruses. TLR9 is expressed on pDC, B cells and monocytes/macrophages. CpG DNA is 
recognized in the endosome following nonspecific uptake into the cells and the activation 
of TLR9 leads to the induction of MyD88 dependent signaling pathway. Stimulation of 
TLR9 triggers B-cell proliferation and secretion of antibodies, secretion of Type 1 cytokines 
and chemokines. [84] 
Through the intracellular domains, TLRs interact with several adaptor proteins to activate 
transcription factors, leading to the production of inflammatory cytokines and the activation 
of the adaptive immunity. Common polymorphisms in TLR genes have been associated 
with increased susceptibility to or protection against several infectious diseases, such as 
tuberculosis (TLR2), bacterial sepsis (TLR4), meningococcemia (TLR4), Legionnaire’s 
disease (TLR4, TLR5) and infection with respiratory syncytial virus (TLR4) [85-92]. Rare 
inherited immunodeficiencies are associated with mutations affecting molecules involved 
in TLR signaling pathways (IRAK4, IKKg and IkBa) [93]. These data clearly demonstrate 
that mutations in TLRs and their associated signal transduction molecules can have a 
dramatic influence on individual susceptibility to human diseases [94-95].  
 Introduction 
TLR9 and HIV 
 
While most HIV-positive patients develop AIDS within 10 years, some progress to 
profound immunodeficiency in 1–5 years (rapid progressors) and others remain 
immunocompetent for up to 20 years. It has been clearly demonstrated that genetic 
variations in the host can influence disease progression. In the context of HIV infection, the 
role of SNPs in TLRs may provide relevant information on HIV pathogenesis because the 
in vitro activation and signaling trough TLR9 (and TLR4, TLR2) and might enhance HIV 
replication. Furthermore, HIV may impair the in vitro immune response after TLR4 and 
TLR2 stimulation. Genetic variants of TLR9 have been associated with the rate of disease 
progression in adults [96-98]. Specific variants of TLR9 were found to be associated with 
risk of mother-to-child transmission (MTCT) of HIV-1, and data regarding their role in 
pediatric HIV-1 disease progression are available in Fregujas’ study. Functional study 
demonstrated a critical role of the G allele of the rs352140 SNP on TLR9 expression. 
In this way, TLR9 may also contribute to effects of HIV on the liver. TLR9 binds CpG-DNA 
of bacterial origin but more recently, it has been shown that TLR9 can also be activated by 
hepatocyte-derived apoptotic DNA fragments. HIV can induce hepatocyte apoptosis in 
vitro via binding of gp120 to CXCR4 even in the absence of productive infection and 
intrahepatic apoptosis is increased in the setting of HIV-HBV coinfection. Signalling 
through TLR9 has also been shown to suppress HIV replication in ex vivo lymphoid tissue 
blocks which correlated with production of chemokines such as CXCL-10 and 12 and CCL 
3, 4, and 5. Therefore, indirect effects of HIV on TLR9 may also contribute to liver disease 
in the setting of HIV infection. 
 
TLR9 and HBV 
 
HBV has also been shown to impair TLR9 signaling in plasmacytoid DCs (pDCs) leading 
to reduced IFN-α production [100] which may be another mechanism for evasion of the 
immune system. TLR9 expression is increased in patients with chronic HBV compared to 
uninfected controls, and TLR9 expression significantly correlates with HBV DNA levels in 
plasma, suggesting a link between TLR9 expression and viral replication. Given the direct 
and indirect effects of HIV on TLR9, it is possible that, in the setting of HIV-HBV 
coinfection, TLR9 signaling in the liver by both HIV and HBV could result in an increase in 
chemokine production and a proinflammatory response. 
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TLR9 and HCV 
 
HCV has adapted multiple methods of evading the host innate immune response by down 
regulating signaling through TLRs 2, 4, 7, and 9 by binding to and interfering with MyD88 
and TRIF in multiple cell types including hepatocytes, macrophages, and plasmacytoid 
(p)DCs [99-100]. HCV has also been shown to cleave mitochondrial antiviral signaling 
protein (MAVS) which forms part of the viral sensing TLR signaling cascade, inhibiting 
IFN-α/β production, and transcription of antiviral ISGs [101]. Recent studies have also 
shown a potential role for TLR7 and 9 agonists in promoting clearance of HCV [102–104]. 
This would suggest that HCV would contribute to a reduction in the antiviral response in 
patients with HIV-HCV coinfection. 
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CHAPTER 4 
 
HEPATITIS C VIRUS 
 
Hepatitis C virus is a major causative agent of liver disease worldwide. An estimated 3% of 
the world’s populations are chronic carriers of the virus, including approximately 1,6 million 
of Italians. Each year, 3 to 4 million people are newly infected with HCV, primarily through 
contact with infected human blood by sharing needles in intravenous drug use or by 
contaminated blood transfusions. Acute infection is most commonly asymptomatic but can 
be accompanied by fatigue and jaundice with 80% of infected individuals progressing to a 
chronically infected state. Chronic infection is often characterized by the development of 
hepatitis, steatosis, fibrosis and liver cirrhosis approximately 20 to 30 years after infection. 
Some patients will eventually die of HCV due to extensive liver damage, primarily due to 
the host immune response, or the development of hepatocellular carcinoma (HCC). 
Currently there is no vaccine for HCV and only 54% of HCV infected individuals respond 
positively to combined therapy of pegylated interferon alpha-2b plus ribavirin, depending 
on HCV genotypic variation and other underlying health problems. Continued HCV 
research is clearly necessary to develop an effective vaccine or antiviral therapy for this 
devastating disease. 
 
4.1 HCV structure  
 
4.1.1 Virus particles 
 
HCV is an enveloped virus with a positive sense RNA genome in the Hepacivirus genus of 
the Flaviviridae family. Each virus particle is approximately 55-65 nm in size [105,106] 
Electron microscopy (EM) of the virus has been hampered by the lack of a cell culture 
system that produces a sufficient amount of 2 virus for visualization. However, recent work 
using the JFH-1 cell culture system has allowed for further characterization of the virus. By 
examining other viruses of the Flaviviridae family, it is believed that HCV has an 
icosahedral arrangement in which the structural glycoproteins E1 and E2 are embedded 
into a bi-layer lipid envelope derived from the host cells. The core protein forms the 
nucleocapsid of the virus that encloses the RNA genome [107]. There are three forms of 
the virus present in the serum of infected individuals including free virions, immunoglobulin 
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associated virions and virions associated with very-low-density and low-density 
lipoproteins [108,109]. 
 
4.1.2 Positive sense RNA genome 
 
Hepatitis C virus contains a positive sense, single stranded RNA genome of approximately 
9.5 kb. The genome consists of a single open reading frame flanked by 5’ and 3’ 
untranslated (UTR) regions which are important for replication of the genome. The highly 
conserved 5’ UTR is 341 nucleotides long and contains the internal ribosome entry site 
consisting of four major RNA domains with extensive secondary structure. The entire 5’ 
UTR is believed to be important for IRES activity and HCV translation. The 3’ UTR is 
potentially important in initiating viral replication. It consists of a poly (U)/polypyrimidine 
tract, a variable 40 nucleotide sequence, and a highly conserved 98 nucleotide sequence 
with stable secondary structure[110,111].  
 
4.1.3 HCV genotypes and quasispecies 
 
The discovery of HCV was unique in that the existence of the virus was confirmed using 
molecular cloning techniques rather than direct biological methods. The viral sequence 
was first obtained by extracting all nucleic acid from the serum of a non-A non-B hepatitis 
infected chimpanzee, creating cDNA clones and identifying the clone corresponding to the 
HCV genome [112]. Using these methods, different strains of HCV were indentified and 
categorized into at least six major genotypes based on nucleic acid sequence alone. 
Genotypes are approximately 65% identical across the whole HCV genome. Within each 
genotype, subtypes are also evident with approximately 80% nucleic acid similarity [113]. 
The different genotypes have different geographical distributions and prevalence, with 
genotype 1 being the most prevalent genotype in North America and Europe while 
genotype 4 is most common in Egypt and North Africa and genotypes 5 and 6 are most 
common in South Africa and Hong Kong. Genotypes 2 and 3 are common in North 
America, Europe and Japan, but to a lesser extent than genotype 1. A high number of 
subtypes are evident in Africa and Southeast Asia, suggesting that this region may be the 
original source of HCV as fewer subtypes are evident in Europe and North America [103]. 
Currently, genotyping of the virus in an infected individual is accomplished by DNA 
hybridization, restriction length fragment polymorphism, direct nucleotide sequencing using 
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polymerase chain reaction, and serologic genotyping. Many of the current methods, 
excluding direct nucleotide sequencing, cannot discriminate between viral subtypes. 
It has become very clear that the HCV genotype is clinically relevant. In acute infection, 
the rate of progression to chronic infection has been related to genotype, with an 
increased number of genotype 1 infected individuals progressing to chronicity in 
comparison with other genotypes [114]. Perhaps more importantly, 4 treatment response 
rates to combination therapy are directly correlated with HCV genotype. Genotype 1 or 4 
infected individuals will only respond to treatment approximately 40-50% of the time, and 
only with a longer course of therapy than genotype 2 and 3 infected individuals who are 
able to clear the virus in approximately 70 to 80% of cases with a shorter treatment 
duration. The reason for this dramatic difference between genotypes is largely unknown, 
but may be related to an interferon sensitivity determining region in the NS5a protein. 
Interestingly, HCV genotype has also been correlated with the development of steatosis in 
HCV infected individuals. Several studies have shown that a substantially increased 
number of HCV genotype 3a infected patients have steatosis, even in the absence of 
contributing factors such as obesity, diabetes and alcoholism. Furthermore, steatosis is 
abolished upon successful treatment and clearance of the virus, suggesting that HCV 
genotype 3a may play a direct role in altering hepatic lipid metabolism that is not as 
evident with other genotypes. 
Within each HCV infected individual, many different sequences of the virus exist which are 
90-99% identical at the nucleotide level and are members of the same infecting genotype. 
These populations of virus, called quasispecies, are generated by the error prone nature of 
the HCV RNA-dependent RNA polymerase during genomic replication. These 
quasispecies populations exist in high numbers during acute infection; as infection 
progresses, the number of dominant quasispecies population decreases with the major 
quasispecies strain changing intermittently. The role of these quasispecies populations is 
twofold. Firstly, high mutation rates can result in the development of new viral strains that 
have increased viral fitness over the parent strain. Secondly, viral quasispecies likely serve 
as a mechanism for immune evasion and viral persistence. As the immune system mounts 
an antibody response against a particular viral epitope, the virus quickly mutates and the 
dominant viral population changes to one that the immune system no longer recognizes. In 
a similar fashion, the virus can also quickly generate mutants that are resistant to antiviral 
drugs. The high mutability of the HCV virus poses several challenges to the development 
of an effective vaccine or antiviral drug.  
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4.2 HCV proteins 
 
The HCV genome is translated into a polyprotein that is subsequently cleaved into 
approximately 10 proteins in the sequence Core-E1-E2-p7-NS2-NS3-NS4a-NS4b-NS5a- 
NS5b. The Core, E1, E2 and p7 proteins are considered structural proteins of the virus 
while NS2, NS3, NS4a, NS4b, NS5a and NS5b are non-structural proteins. 
 
4.2.1 Structural proteins 
 
The core protein is cleaved from the polyprotein via host signal peptidase to form a 191 
amino acid immature form of the protein. The core protein is then cleaved between amino 
acids 173 to 179 by host Signal Peptide Peptidase (SPP) to form the mature protein [115]. 
The core protein is a dimeric alpha-helical protein that can bind RNA and consists of two 
major domains. The D1 domain is primarily hydrophilic and is located in the N-terminus 
while the D2 domain is primarily hydrophobic and located in the C-terminus. D2 assists in 
the folding of the protein as well as membrane and lipid droplet association. The core 
protein is localized on the endoplasmic reticulum and on the surface of lipid droplets in 
infected cells. Some studies have also shown a small amount of core protein in the 
nucleus and on mitochondria, but this localization has not been observed in infected cells. 
Localization of core with lipid droplets is also mediated by proteolitic cleavage by SPP 
[116]. Mature core proteins form the nucleocapsid of the virus. However, many studies 
have shown alternative roles for the core protein in the pathogenesis of HCV including 
apoptosis, insulin resistance, cell cycle, and lipid metabolism. Interestingly, the core 
protein-encoding region also contains a +1 alternative reading frame that results in 
translation of the ARF (alternative reading frame) protein. The F protein does not contain 
an AUG start codon, so translation of this protein is a random event. No known function of 
the F protein is currently known. Although antibodies against it are present in HCV infected 
individuals, it is not required for viral replication [117].  
The E1 and E2 proteins of HCV are envelope glycoproteins that are essential for virus 
entry and form heterodimers on the viral envelope. The E2 protein contains a 
hypervariable region that mutates frequently to allow for the development of immune 
escape variants [117,118].  
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The p7 protein has recently been found to have ion-channel activity and it is essential for 
virus infectivity. As such, new research has been directed toward developing antiviral 
compounds to block the function of this protein [119].  
 
4.2.2 Non-structural proteins 
 
The NS2 protein is a hydrophobic protease that cleaves the HCV polyproteins between 
NS2 and NS3 and it may function as a novel cysteine protease. Efficient cleavage of 
NS2/3 is required for HCV replication, but the presence of NS2 is not required for genome 
replication. Following cleavage, NS2 is localized in the ER membrane. Besides its 
protease activity, NS2 appears to be involved in apoptosis, cell proliferation, innate 
immunity and lipid metabolism. The NS3 protein is a protease and RNA helicase. Protease 
activity of NS3 is mediated by the NS4a protein. Both proteins are localized on the ER. 
The NS3/4a protease complex cleaves the HCV polyprotein downstream of NS3 and this 
action is essential for formation of the viral replication complex. NS3/4a is able to inhibit 
the host innate immune response via disrupting the RNA helicase 
retinoic acid-inducible gene-I (RIG-I) pathway by cleaving Cardif, an adaptor protein of 
interferon regulatory factor-3. The function of the NS3/4a helicase activity is still unknown. 
The NS4b protein is present on the ER membrane and induces intracellular membrane 
changes that may be involved in the formation of the replication complex membranous 
webs. It also contains a nucleotide binding motif that hydrolyzes GTP. NS4b is thought to 
play a major role in viral replication, assembly and release as well as lipid metabolism. 
NS5a is also an ER-associated protein that is particularly multi-functional. It can bind to 
HCV RNA and it is essential for viral replication [120]. It can be hyperphosphorylated in 
order to inhibit viral replication. NS5a is also able to decrease the immune response via 
inhibition of interferon-induced double stranded RNA activated protein kinase PKR. NS5a 
may also play a role in mediating lipid metabolism as it interacts with core proteins on the 
surface of lipid droplets and it also interacts with apolipoproteins. NS5b is an RNA 
dependent RNA polymerase that synthesizes RNA using an RNA template. It is also 
localized on the ER membrane and it is essential for viral replication. As such, it is a prime 
target for the development of antiviral compounds [121]. 
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 4.3 HCV LIFE CYCLE 
 
4.3.1 Receptors and entry 
 
The entry of HCV into a naïve host cell appears to be a complicated, multi-step process 
involving several different host receptors. The initial entry steps have only been recently 
characterized thanks to the newly developed infectious cell culture system, and many 
details are still to be discovered. Heparin, a glycosaminoglycan, has been long suspected 
to play a role in viral entry with several studies showing inhibition of viral attachment in the 
presence of heparinase, an enzyme that disrupts heparin. Low-density lipoprotein receptor 
(LDLR) is very likely a critical component of viral attachment. HCV in the serum of infected 
patients is bound to low density and very low-density lipoproteins. Adsorption of HCV from 
the serum of infected patients can be inhibited through the use of antibodies against LDLR 
suggesting that the association of HCV with lipoproteins is an important step in attachment 
of the virus. CD81, a cell surface protein in the tetraspanin family, is considered one of the 
major players in HCV attachment. Antibodies against CD81 effectively inhibit HCV 
infectivity in different models. In addition, HepG2 and HH29 hepatoma cells, which are not 
normally permissive to HCV infection, can be infected following ectopic expression of 
CD81. However, expression of CD81 in other non-permissive cell lines does not allow 
HCV infection to occur, suggesting that other host cell factors may be involved in the 
attachment and entry process. Scavenger receptor class B type I (SR-BI) is another cell 
surface protein that may be involved in viral attachment and entry. SR-BI is a receptor for 
lipoproteins and it can also change the lipid composition of membranes. Blocking of SR-BI 
with antibodies can prevent virus entry. It is still unclear whether SR-BI is interacting 
directly with the virus proteins or if it is interacting with virus associated lipoproteins to 
mediate virus entry as both mechanisms have been observed [122-126]. Recently, two 
tight junction cell proteins Claudin-1 and Occludin have been shown to be involved in HCV 
entry. Claudin-1 can be ectopically expressed in non-permissive, non-hepatic 293T cells 
and allow HCV infection to occur. Knock-down of Claudin-1 in permissive Huh7 cells can 
reduce HCV infectivity. It has also been found that Claudin-1 and Occludin are involved in 
late entry of the virus into the cell, which likely occurs through interaction with the tight 
junctions. The use of the tight junctions by HCV may also allow for cell to cell spread of the 
virus. It has been shown that HCV entry is mediated by endocytosis in a pH-dependant 
manner. In addition, knock-down of clathrin, a critical component of the endocytotic 
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vesicles, prevents HCV infection. Fusion of the virus envelope with the endosome 
membrane is not well characterized and both E1 and E2 are likely involved in the process 
[127].  
 
4.3.2 Replication, assembly and release 
 
HCV replication occurs in a membrane associated replication complex that contains 
several viral and host proteins and replicating RNA. The positive strand of the virus RNA 
genome is made into a negative strand that is then used to make more positive strand 
copies for packaging. The NS5b protein is the major player in the synthesis of both the 
positive and negative strands. The HCV replication complex appears to contain a 
membrane alteration called a membranous web that can be observed by electron 
microscopy in infected cells in vitro and in vivo, as well as in cells expressing the NS4b 
protein alone. The source of the membranous web is likely the ER as most of the HCV 
proteins are associated with the ER upon translation. It is also possible that viral 
replication is occurring on lipid rafts that contain large amounts of cholesterol and 
sphingolipids. Inhibitors of sphingolipid synthesis can prevent HCV replication and both 
non-structural proteins and replicating RNA are found on lipid. Recently, it has been 
determined that lipid droplets play an important role in virus assembly. Core protein 
localizes around lipid droplets where it recruits non-structural proteins and replication 
complexes. Inhibiting lipid droplet localization of core protein decreased the production of 
infectious virus particles. There are also many different host cell proteins with putative 
roles in HCV replication. For example, vesicle-associated membrane protein-associated 
proteins A and B (VAP-A and VAP-B) localize in the ER and bind both NS5a and NS5b 
and are essential for viral replication. Cyclophilin B, a peptidyl-prolyl cis-trans isomerase, 
binds to NS5b and enhances its RNA binding activity. Similarly, p68, and RNA helicase, 
binds NS5b and moves into the cytoplasm from the nucleus to assist in viral replication. 
Very little is known about HCV assembly and release. There are several different forms of 
the virus found in infected serum, including free mature virions, virions bound to low-
density and very low-density lipoproteins, virions bound to immunoglobulins and non-
enveloped nucleocapsids. It is believed that viral RNA can interact with the core protein, 
which then oligomerizes to form the nucleocapsid around the viral RNA. The envelope of 
the virus is then obtained through core interaction with E1 glycoprotein on the ER 
membrane, from which budding occurs. From this point it is thought that the virus is 
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released from the cell after transit through the Golgi apparatus and the secretory pathway 
[128].  
  
4.3.3 Virus-like particles 
 
In the serum of HCV infected individuals, several different forms of HCV can be found that 
differ in both size and density. Currently very little is known about HCV assembly and how 
these different types of HCV particles are formed and secreted. HCV RNA can be found in 
infected serum at a density between 1.03 and 1.25 g/ml. Interestingly, the lower density 
particles appear to be more infectious than the higher density particles when tested in 
chimpanzees. The low-density particles contain high amounts of triglycerides, as well as 
HCV RNA, core protein and apolipoproteins B and E (ApoB and ApoE). Triglycerides 
along with ApoB and ApoE are the major components of very-low density lipoproteins 
(VLDL) and low-density lipoproteins (LDL) which are particles packaged in the ER of 
hepatocytes to be secreted into the bloodstream and transport their triglyceride load to 
adipocytes for storage. During HCV infection, assembled virus particles are hypothesized 
to use this pathway to acquire ApoB, ApoE and triglycerides prior to secretion from the 
cells. Virus particles that do not obtain the necessary triglycerides and apolipoproteins are 
not secreted from the cell and undergo degradation. Exploitation of the VLDL assembly 
pathway by HCV ultimately decreases lipid export from the cells and could be an important 
factor in the development of steatosis in infected patients. The addition of apolipoproteins 
and triglyceride to the virus particle could also be advantageous to the virus as it could be 
providing a mechanism of immune escape by hiding viral epitopes and also by increasing 
the number of potential receptors (ie. CD81, LDLR and SR-BI) for attachment [129-133].  
Another fraction of the HCV population in infected serum appears to be nonenveloped. 
These particles have a higher density and vary in size. The core protein is displayed on 
the surface of these particles and antibodies against core protein are a hallmark of HCV 
infection. Currently it is unknown whether these nonenveloped particles are infectious or 
what role they play in the course of HCV infection and pathogenesis [134]. 
 
 
 Introduction 
4.4 HCV MOLECULAR PATHOGENESIS 
 
4.4.1 Cell survival and apoptosis 
 
Apoptosis is a very important mechanism for the removal of virus infected cells and many 
viruses inhibit apoptotic pathways in order to ensure their continued survival. However, in 
chronic HCV infection an increased amount of apoptosis is observed in the liver although it 
is unknown whether HCV infected or uninfected hepatocytes are undergoing apoptosis 
[135,136]. Three major death ligands, CD95 Ligand, Tumor Necrosis Factor α (TNFα) and 
Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL), are considered to be 
the major players in inducing hepatocyte apoptosis. Infection with HCV up-regulates all 
three of these death ligands. In addition, CD95 Ligand induced apoptosis was observed in 
uninfected bystander cells of HCV infected livers [135-138]. Interestingly, TRAIL can also 
induce the development of steatosis [39]. When specific HCV proteins were examined for 
their influence on apoptosis, results showed that all HCV proteins have both pro-apoptotic 
and anti-apoptotic effects depending on the model being used and it is currently unclear as 
to what occurs in vivo. Core proteins have been shown to inhibit TNFα and CD95 Ligand 
induced apoptosis in cell culture, while other studies have shown that the presence of core 
protein, including those expressed in transgenic mice, cannot inhibit CD95 Ligand induced 
apoptosis [140-142]. Core proteins can directly interact with several pro-apoptoic proteins 
including CD95, TNF-R1 and lymphotoxin-β. However, it can also bind to FADD, C-FLIP 
and Smad3 to prevent apoptosis. Core can also increase phosphorylation of Akt, an 
important protein involved in cell survival [143]. Core proteins also induce oxidative stress 
that can lead to increased susceptibility to apoptosis (Okuda et al., 2002; Machida et al., 
2006). The E1 protein inhibits TRAIL-induced apoptosis, while E2 can induce caspase 
dependent apoptosis. NS2 can inhibit CIDE-B induced apoptosis, while NS3 can cleave 
Cardif and prevent RIG-I associated apoptosis. NS4a can induce caspase-8 independent 
apoptosis from the mitochondria. NS5a has shown both anti-apoptotic and pro-apoptotic 
effects. It can inhibit Baxmediated apoptosis by acting as a bcl-2 homologue. It can also 
activate the PI3K/Akt pathway and prevent p53- mediated apoptosis. However, direct 
apoptosis has been observed in cells expressing NS5a. All of these results suggest an 
important but complex role of HCV and its proteins in mediating cell survival and apoptosis 
that is yet to be fully explained. The anti-apoptotic potential of this virus may influence the 
development of hepatocellular carcinoma, a common complication of HCV infection [144]. 
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4.4.2 Immunopathogenesis 
 
It is generally accepted that liver damage during HCV infection is primarily caused by the 
reaction of the immune system to virus infection, although some cytopathic effects of the 
virus such as increased apoptosis and the development of steatosis have been observed. 
HCV itself has also been shown to alter both the innate and adaptive immune responses. 
The NS3/4a protease is able to induce cleavage of mitochondrial antiviral signaling protein 
(MAVS), which results in the impairment of RIG-I mediated interferon production in the 
presence of dsRNA.  During viral infection, cytotoxic lymphocytes are critical to the 
efficient removal of infected cells. In acute HCV infection, the appearance of HCV specific 
cytotoxic CD8+ T cells (CTLs) is associated with decreased viremia. Activation of HCV 
specific CD38+ CD69+ T cells coincides with inflammation and hepatitis during acute 
infection, suggesting a role for these non-interferon γ producing CTLs in causing immune 
mediated liver damage. Regulatory T cells have been shown to have an important role in 
suppressing HCV-specific CTL responses, as increased numbers of regulatory T cells are 
present in chronically infected patients versus those who have spontaneously recovered 
from their infection. Therefore, it is likely that CTLs play a role in both controlling viremia 
and causing liver damage during HCV infection.  
 
Natural Killer (NK) cells are also important lymphocytes involved in clearing viral infection. 
NK cells can directly or indirectly induce apoptosis in virally infected hepatocytes that may 
contribute to both viral clearance and liver damage. HCV infected cells have decreased 
MHC class I protein expression, which is a primary inducer of NK mediated cell lysis. 
Conversely, NK cells may actually protect the liver from progression to fibrosis by 
removing activated hepatic stellate cells, the main fibrogenic cell type in the damaged liver. 
Indeed, increased NK cytolytic activity is inversely correlated with the fibrosis stage in the 
liver [145].  
 
γδ T cells are also important lymphocytes in the liver during viral infection. Increased levels 
of γδ T cells are present in the livers of chronic HCV patients [146]. However, γδ T cells 
have also been shown to have a protective effect on the liver during chronic viral infection, 
suggesting that they too may also decrease liver injury during infection [147].  
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4.4.3 Lipid metabolism 
 
One of the major functions of the liver is to metabolize lipids. As such, infection of 
hepatocytes with HCV is likely to affect cellular pathways involved in lipid metabolism. 
Indeed, patients infected with HCV show clinical disease associated with lipid metabolism 
defects such as steatosis and hypolipoproteinemia [148]. In vitro studies have also 
demonstrated an important role for the virus in exploiting lipid metabolism pathways in 
order to produce virus particles and evade the immune system that contribute to HCV 
pathogenesis [149].  
 
 
4.5 HCV CLINICAL CHARACTERISTICS 
 
4.5.1 Acute viral infection 
 
Upon infection with HCV, most patients enter an acute phase that is largely asymptomatic. 
Most of the infected individuals (~80%) will progress to chronic HCV infection while the 
other 20% will clear the virus within the first 3 months after infection. The asymptomatic 
nature of the acute stage of infection results in difficulty in diagnosing and reporting HCV 
infection, as well as difficulty in studying the aspects of the immune response that allow for 
viral clearance during this time. The greatest risk of infection with HCV is through 
intravenous drug use, unprotected sex, exposure during medical procedures, vertical 
transmission from mother to child, or needle injury in health care professionals. Blood 
transfusion prior to 1992 is also an important risk factor (Centers for Disease Control and 
Prevention. Surveillance for acute viral hepatitis United States, 2005. 56th ed. Atlanta, GA: 
Centers for Disease Control and Prevention; 2007. P. 1-24). HCV RNA can be detected in 
the serum approximately 1-3 weeks after exposure. Symptoms include fatigue, jaundice, 
dyspepsia, and abdominal pain but are generally not specific or severe enough to warrant 
consultation of a doctor. Elevated alanine aminotransferase (ALT) levels can be detected 
4-12 weeks after exposure and are the first indication of liver injury. Serum HCV RNA and 
anti-HCV antibody seroconversion is generally used to detect HCV infection. Host and viral 
factors appear to contribute to viral clearance in acute infection including genotype of the 
virus, HIV co-infection, gender, race, age and HLA. A strong cellular immune response is 
also thought to increase viral clearance, and symptomatic infection appears to correlate 
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with viral clearance. Patients who spontaneously clear the virus need to be monitored as 
disease relapse may occur up to 6 months after clearance [150]. 
 
4.5.2 Chronic viral infection 
 
Infection with HCV is one of the leading causes of liver disease worldwide. As previously 
discussed, a small proportion of people are able to clear the virus following an acute 
infection but the majority progress to a chronically infected state. Chronic infection can 
persist for many years without causing the death of the patient. However, most cases 
eventually lead to the development of hepatitis, fibrosis, steatosis and cirrhosis with the 
eventual need for a liver transplant if left untreated. A small number of HCV infected 
individuals will also develop hepatocellular carcinoma. Host factors such as age, obesity, 
alcohol use, gender, race and co-infection with HIV or HBV can increase the rate of 
progression of liver. Genotype does not appear to play a role in disease progression. 
However, the presence of non-alcoholic steatohepatitis can increase progression of 
disease, and infection with genotype 3a is associated with a higher prevalence of 
steatosis. In general, the rate of progression to cirrhosis is unpredictable in chronic HCV 
infection [151].  
 
4.6 HCV GENOTYPING METHODS 
 
4.6.1 Molecular genotyping 
 
Because differences in geographical distribution, disease outcome, and response to 
therapy among HCV genotypes have been suggested, reliable methods for determining 
the HCV genotype may become an important clinical test. The HCV genotype can be 
determined by nucleotide sequencing of a specific PCR-amplified portion of the HCV 
genome obtained from the patient, followed by composition of a phylogenetic tree, which is 
presently the 'gold standard' for the detection and identification of the various HCV 
genotypes and subtypes. Investigators of HCV genotyping have used sequence analysis 
of HCV NS5, core, E1, and 5'-UTRs. Other methods focus on the amplification of defined 
regions of the HCV genome by reverse transcription (RT)-PCR followed by digestion with 
restriction enzymes and restriction length polymorphism analysis (RFLP) (31), 
amplification with genotype-specific primers, hybridization of genotype-specific probes with 
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the amplified products heteroduplex mobility assay, melting curve analysis with 
fluorescence resonance energy transfer probe and DNA enzyme assays. HCV typing can 
also be done by analyzing the sequences of several regions of the virus genome. A 
commercial kit (InnoLipa) for HCV genotyping has been introduced in Europe by 
Innogenetics (Zwijndre, Belgium), which is based on hybridization of 5'-UTR amplification 
products with genotype specific probes . It has been shown that genotyping methods using 
5'- UTR, including InnoLipa, may not discriminate subtype 1a from 1b in 5 to 10% of cases 
and also may not distinguish between subtypes 2a and 2c. Others have used restriction 
enzymes to determine a restriction fragment length polymorphism. In this method, a PCR 
amplified DNA fragment is digested into fragments with different lengths by enzymes 
(restriction endonucleases) that recognize cleavage sites specific for each genotype. 
Investigators have used different regions of the HCV genome for restriction fragment 
length polymorphism, including NS5 and the 5'-UTR. Although the 5'-UTR region is 
sufficiently variable to allow HCV genotypes in most clinical situations, it cannot always 
characterize HCV subtypes and may fail to trace the origin of a de novo infection. The 
NS5b region contains a subtype-specific motif which makes it suitable for epidemiological 
applications. It is difficult to assess the actual prevalence of mixed-genotype infections by 
currently available assays, including direct DNA sequencing, since they are designed to 
identify only the HCV genotype dominant in the population.  
 
4.6.2 Serologic genotyping 
 
More recently, investigators identified genotype specific antibodies that could be used as 
indirect markers for the HCV genotype. Serological typing uses enzyme immunoassays to 
detect the antigenic properties of several specific epitopes encoded by the NS-4 or the 
core regions of the HCV genome. Serologic genotyping has several advantages that make 
it suitable for large epidemiologic studies. These advantages include the low risk of 
contamination and the simplicity of the assay. However, serologic typing seems to lack 
specificity and sensitivity, which limits its usefulness.  
 
4.7 Clinical relevance of HCV genotype 
 
Genotype, viral load, and liver histology are important parameters used in selecting an 
antiviral therapy with the greatest chance of success. Genotyping and subtyping of HCV is 
relevant to the epidemiology of HCV, vaccine development, clinical management, and 
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assessment of the risk-benefit ratio of therapeutic measures against chronic HCV 
infection. It has been postulated that differences in nucleotide sequence could result in 
differential activity of HCV proteins that could alter the rate of HCV replication, sensitivity to 
the antiviral activity of interferon, or pathogenicity of the virus. In recent years, substantial 
evidence has emerged indicating that typing and subtyping for HCV is important clinically; 
genotype 1 in particular cannot be treated efficiently with IFN-alpha, while genotypes 2 and 
3 respond favorably. The causes of variation in treatment response are not well 
understood. Studies of Japanese patients infected with subtype 1b indicated that the 
outcome of interferon therapy was correlated with genetic variability in a portion of the 
NS5A gene (the interferon sensitivity determining region, ISDR), although subsequent 
studies of European patients did not confirm this result. Moreover, genotype 1 infection 
may proceed more rapidly to severe forms of chronic hepatitis, cirrhosis and hepatocellular 
carcinoma, when compared with genotype 2 and 3. 
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CHAPTER 5 
 
INTERFERON LAMBDA 3 GENE POLYMORPHISM (IL28B) 
 
Host genetic factors may predict the outcome and treatment response in hepatitis C virus 
(HCV) infection. Recently, three landmark genome-wide association studies identified 
single nucleotide polymorphisms near the interleukin 28B (IL28B) region, which were more 
frequent in responders to treatment. IL28B encodes interferon (IFN) λ3, a type III IFN 
involved in host antiviral immunity. Favorable variants of the two most widely studied 
IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of 
early viral clearance and sustained viral response in patients with genotype 1 HCV 
infection. IL28B has been also implicated in the development of chronic HCV infection 
versus spontaneous resolution of acute infection and suggest that IL28B may be a key 
factor involved in host immunity against HCV.  
 
 
 
L28B gene locus on human chromosome 19. The 3 most strongly associated SNPs are in the genome 
regions flanking the IL28B gene. Nucleotide numbers on chromosome 19 are indicated for three SNPs and 
for the start of the coding region of the IL28A and IL28B gene. 
 
 
5.7.1 IL28B polymorphism Rs12979860  
 
Rs12979860 is a SNP on chromosome 19q13 and is strongly associated with sustained 
virologic response (SVR) in genotype 1 HCV-infected subjects [152]. Results in three 
possible genotypes: the C/C genotype was associated with 2.5 or greater rate (depending 
on ethnicity) of SVR compared to the T/T genotype, and the C allele may favor 
 Introduction 
spontaneous clearance of HCV [152]. The rs12979860 polymorphism also may explain 
much of the difference in response between different population groups: in fact, the 
genotype leading to better response presents with greater frequency in European than in 
African populations [152]. Moreover, HCV-infected patients with C/C genotype showed 
association with lower steatosis severity grade in HCV genotypes 2, 3, and 4, and also in 
HCV/HIV-infected patients even though prior non-responders [153-158]. The C allele also 
appears to affect positively early viral kinetics in patients with chronic hepatitis C receiving 
interferon-free treatment [159,160]. The C allele may differentially regulate the course of 
genotype 2 and 3 infection [161,162]. IL28B plays a determinant role in natural clearance 
of HCV and spontaneous resolution of HCV infection [163]. However, rs12979860 
homozygosity is not associated with resistance to HCV infection in exposed uninfected 
patients [164]. Studying the impact of donor and recipient genotypes of IL28B 
rs12979860C>T SNP on hepatitis C virus (HCV) liver graft reinfection revealed a dominant 
but not exclusive impact of the donor rather than the recipient genetic background on the 
natural course and treatment outcome [165]. Interestingly, the risk of developing post-
transplant diabetes mellitus is significantly increased in recipients carrying the IL28B 
rs12979860C>T SNP [166]. 
 
5.7.2 IL28B polymorphism rs8099917 
 
The minor allele (T/G or T/T) was associated with progression to chronic HCV infection 
and also with failure to respond to therapy, with the strongest effects in patients with HCV 
genotype 1, 2, or 4. However, T/T genotype may contribute to the increased viral 
clearance rate and better virological responses in Taiwanese patients with a lower daily 
viral production rate than Western patients. Even though there are no studies considering 
multiethnic cohorts, a recent meta-analysis evidenced that rs8099917 T/T had slight 
predictive value in Asian patients. A further study reported that combination analyses of 
SNP of rs8099917 in recipient and donor tissues and mutations in HCV RNA allowed 
prediction of SVR to PEG-IFN/RBV therapy in patients with recurrent HCV infection after 
orthotropic liver transplantation. Another study revealed the high prevalence of the 
rs8099917 G allele in HCV/HIV-1-coinfected patients as well as its strong association with 
treatment failure in HCV genotype 1-infected patients. The rs8099917 T/T genotype is 
associated with higher levels of apoB-100 and LDL cholesterol in genotype 1-HCV-
infected patients. 
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5.7.3 Combined IFN3λ Polymorphisms 
 
Both favorable genotypes for rs12979860 (C/C) and rs8099917 (T/T) were associated with 
spontaneous HCV clearance, possibly interacting in synergy with female sex. On the other 
side, IL28B variants associated with poor response to interferon therapy may predict 
slower fibrosis progression, especially in patients infected with non-1 HCV genotypes. 
Concerning HCV genotype 3-infected subjects, IL28B polymorphisms are associated with 
RVR but not SVR to PEG-IFN therapy [167]; other studies showed that IL28B 
polymorphisms are strongly associated with the first phase viral decline during PEG-
IFN/RBV therapy of chronic HCV infection, irrespective of HCV genotype, and in genotype 
1– 4 HIV/HCV-coinfected patients [166-169]. These reports suggest that IL28B 
polymorphisms could play a role in blocking the production or release of virions in the first 
phase viral decline [170]. Treatment outcome in HCV-infected patients may be also 
influenced by viral polymorphisms within the viral core and NS5A proteins, even though it 
has been clearly demonstrated that IL28B polymorphisms and HCV core amino acid 70 
substitutions contribute independently to an SVR to PEG-INF/RBV therapy [171]. A further 
study demonstrated that SNPs rs8099917 and rs12979860 used alone may be useful for 
predicting the outcome of HCV treatment, and in a rational and cost-effective approach, 
determination of only one of these two SNPs is sufficient for predicting SVR. Because of 
the highest predictive SVR associated with rs12979860 C/C compared with the rs8099917 
T/T, rs12979860 determination alone is sufficient for predicting interferon response [176, 
177], even in HIV/HCV-coinfected patients [178]. However, there is evidence that a 
significant proportion of heterozygous carriers of the rs12979860 T nonresponder allele 
can profit with respect to SVR prediction by further determination of the rs8099917 SNPs 
[179].  
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AIM 
 
HIV 
 
Toll-like receptors (TLR) play a crucial role in the host’s innate immunity and may influence 
HIV-1 disease progression. The transcription factor IRF-5 is an important player in the 
TLR-MyD88 signaling cascade. We investigated the impact of two SNPs in TLR9 gene, 
rs352139 and rs352140, and two SNPs in IRF5 gene, rs10954213 and rs11770589, on 
CD4 count, HIV viral load, and clinical progression in a cohort of HIV-infected patients.  
 
 
HCV 
 
In patients with chronic hepatitis C, the hepatitis C virus (HCV) RNA level is an important 
predictor of treatment response. To explore the relationship of HCV RNA with viral and 
demographic factors, as well as IL28B genotype, we examined viral levels in an ethnically 
diverse group of injection drug users (IDUs).  
  
 
 
 
 
MATERIAL AND METHODS
 METHODS  
1. HIV STUDY: 
1.1 Patients: 
All individuals of this study were enrolled by the Departments of Infectious diseases of the 
Luigi Sacco Hospital in Milan and written informed consent was obtained before 
enrolment. For this project a total of 262 HIV-infected patients were enrolled of which 99 
were LTNP and 163 progressors. 
 Progressor patient under ARV therapy; 
 LTNP with HIV plasma viremia has been under the threshold for at least 8 years, 
CD4+ ≥ 500 cell/ul years, never under teraphy, in absence of HIV sympthoms and  
opportunisitc infections 
.  
1.2 Patients collection and samples processing  
  
Whole blood was collected by venipuncture in Vacutainer tubes containing EDTA 
(ethylenediaminetetraacetic acid) (Becton Dickinson, Rutherford, NJ, USA). Samples were 
centrifugated 1400rpm for 10 minutes, plasma obtained was collected and stored at -20°C 
for subsequent analyses. The remaining sample, composed by erythrocytes, PBMC, 
granulocytes and platelets, was diluited in PBS (phosphate buffered saline) (PBI 
International, Milano, Italy) and separated thanks to a density-gradient centrifugation on 
lymphocyte separation medium (Ficoll-Hypaque) (Cedarlane Laboratories Limited, Hornby, 
Ontario Canada) for 25 minutes at 2300rpm. PBMC are localized between the phase of 
fycoll-hypaque and the phase including granulocytes and erythrocytes, they are collected 
and washed twice in PBS for 10 minutes at 1900 rpm. Cellular pellet was resuspended in 
PBS and washed twice in phosphate-buffered saline (PBS) (PBI International, Milano, 
Italy). Cellular count was conducted using an automatic cell counter. 
 
1.3 Cell count 
 
The number of viable leukocytes was determined by the use of an automatic cell counter 
ADAM-MC (Digital-Bio, NanoEnTek Inc., Corea). ADAM-MC automatic cell counter 
measures total cell numbers and cell viabilities by cutting edge detection technologies. The 
 instrument is able to count the cells thanks to the use of propidium iodide, a fluorescent 
dye that intercalates in the DNA of cell characterized by damage cell membranes. It‟s 
based on two different solution, AccuStain Solution T is composed by propidium iodide 
and lysis solution while AccuStain Solution N is composed by propidium iodide and PBS. 
AccuStain Solution T allows to count all cells present in the sample while AccuStain 
Solution N just non-viable cells.  
To evaluate cell concentration, a small quantity of sample (30μl) is combined with an equal 
volume of each solution. Samples prepared in this way are directly transferred in a 
disposable slide and this is read by the instrument. A green laser (532nm) is focalized on 
the slide and the cells colored are detected by a CCD camera (B/W CCD). On the screen 
it‟s shown total cell count, the count of non-viable cells and the vitality of each sample is 
calculated by ADAM-MC software. The number of cell/ml is obtain with the substraction of 
total number of non-viable cells from the number of total cells. 
 
1.4 Genotyping of the SNPs in TLR9 and IRF5 gene 
 
Two single nucleotide polymorphisms (SNPs) rs352139 and rs352140 of TLR9 were 
genotyped by sequencing 163 progressors and 99 LTNP HIV-1-positive patients. PCR was 
carried out in a reaction mixture containing 40 ng of DNA, 10 μl of HotStar Taq Master Mix 
(Qiagen, Germantown, MD) and 100 pmol of each of the following primers: for rs352139 
TLR9,  forward 5’-GCCAGGGATTGGTTAAGTGA-3’ and reverse5’-
GTAGGAAGGCAGGCAAGGTA-3’; for rs352140 TLR9, 5’-
CAGTCAATGGCTCCCAGTTC-3’ and reverse 5’- TTGGCTGTGGATGTTGTTGT-3’; for 
rs10954213/rs11770589, forward 5-CCCTGATTTCCCTGGTTTG-3 and reverse 5’-
AGCCAGCCAGGTGAGTGTT-3. The reaction mixture was denatured at 95°C for 15 
minutes and cycled 35 times at 94°C for 45 seconds, Ta = 55°C for 45 seconds, 72°C for 
60 seconds, with final extension at 72°C for 10 minutes. PCR product was treated with 
Exosap-IT (USB Corporation, Cleveland, OH) to removed excess primers. 3.5 μl out of 20 
of purified DNA product was combined with 2.0 μl of Big Dye terminator (ABI Prism Big 
Dye Terminator cycle sequencing ready reaction kit v3.1, Applied Biosystems, Foster City, 
CA) and 100 pmol of forward primer.  
 
The sequencing reaction was carried out for 30 cycles of denaturation (96°C/1 m), 
annealing (50°C/30 s) and extension (60°C/ 4 m). Excess dye terminators were removed 
 using DyeEx 96 Kit columns as per Manufacturer’s instructions (Qiagen Inc. Germantown, 
MD). Electrophoresis was performed on ABI Prism 3730 XL instrument (Applied 
Biosystems, Foster City, CA). 
 
1.5 Statistical analysis 
 
Association analyses were conducted by chi-square test using 2 × 2 and 2 × 3 contingency 
tables. When 1 or more variables in the contingency table were ≤ 5, Fisher’s exact test 
was used. Two side probability values (p2-value) < 0.05 were considered to be statistically 
significant. 
Calculation of linkage disequilibrium (LD) parameters (r2 and D’) based on genotype data 
from 262 patients was performed using LDPlotter tool from https://pharmgat.org/Tools 
 
2. HCV STUDY METHODS: 
 
2.1 Subjects and Data Collection  
As previously reported, UHS investigators recruited IDUs from six San Francisco Bay area 
neighborhoods (10). All individuals 18 years of age or older who had injected illicit drugs 
within the past 30 days or who had previously participated in UHS were eligible for 
enrollment. Study participants received modest monetary compensation. Although some 
participants had received hepatitis B vaccine (9), few, if any, were treated for HBV or HCV 
infection. Participants were not asked about treatment for HCV infection during 1998-2000, 
but in 2002 only 3% of UHS participants reported interferon-based treatment for HCV 
infection, (11) thus the vast majority of subjects in this study had never received treatment 
for chronic hepatitis C. Among the 237 subjects in this analysis who tested positive for 
human immunodeficiency virus type 1 (HIV-1), 47 (19.8%) reported taking at least one 
anti-retroviral drug at the time of enrollment. 
Trained staff obtained informed consent from the participants, including explicit written 
consent for host genetic testing. Participants were interviewed using a standardized 
instrument, counseled on reducing infection risks, and referred to appropriate medical and 
social services. Participants were asked about socio-demographic characteristics and their 
injection drug history, including age at first injection. Blood samples were collected by a 
trained phlebotomist. Further details about UHS are provided elsewhere.(10)  The study 
 was approved by the Committee on Human Subjects Research at University of California, 
San Francisco and an Institutional Review Board of the National Cancer Institute. 
We assessed possible repeat enrollment by comparing demographic information, including 
gender, birth date, race and site of enrollment. Enrollees who appeared very similar 
demographically were evaluated by DNA testing (as described below). Among 2296 UHS 
participants, 2092 were positive for HCV antibody of whom 2073 had sufficient specimen 
to be tested for HCV RNA. Among these 2073 participants, 1701 had detectable HCV 
RNA in the plasma and were included in the current study. 
2.2 Viral Serology  
As previously described,(9) to define HCV infection status, we first tested for HCV antibody 
by HCV version 3.0 ELISA Test System (Ortho-Clinical Diagnostics, Raritan, NJ). 
Participants who were positive by HCV EIA were considered to have been infected with 
HCV and those with sufficient archived plasma (n=2073) were tested for HCV viremia by a 
branched-chain DNA assay [VERSANT® HCV RNA 3.0 Assay (bDNA), Bayer-Diagnostics, 
Tarrytown, NY; analytic sensitivity, 2.5x103 copies/ml]. Those positive for HCV RNA were 
considered to have chronic HCV infection and those with a negative result were 
considered to have resolved HCV infection. Methods of testing for HIV-1 and HBV 
infection status in these subjects have been described.(9)   
2.3 Determination of Viral Genotypes 
Total nucleic acid was isolated from 500 µl of serum (Roche MagNa Pure LC Total Nucleic 
Acid Isolation Kit-Large Volume, Roche Diagnostics Corporation, Indianapolis, IN) and 
reverse transcription was performed. PCR was carried out in a reaction mixture containing 
3 µl of cDNA, 10 µl of HotStar Taq Master Mix (Qiagen) and 1 µl of each of the following 
primers: forward 5'- TGGGGTTCTCGTATGATACCC-3’ and reverse 5’-
CCTGGTCATAGCCTCCGTGAA-3’ to amplify the 5’-NS5b region. PCR product was 
purified with Exosap-IT (USB Corporation) and combined with 2.0 µl of Big Dye terminator 
(ABI Prism Big Dye Terminator cycle sequencing ready reaction kit v3.1) and 100pmol of 
primer forward (5’-NC or 5’-NS5B). The sequencing reaction was carried out for 30 cycles 
and electrophoresis was performed on an ABI Prism 3730 XL instrument (Genewiz, South 
Plainfield, NJ, USA). 
 Raw sequence data were analyzed by Sequencher 4.8 Gene codes to trim ambiguous 
sequences. To query HCV genotype, sequences were compared to an HCV database 
operated by the Los Alamos National Laboratory 
(http://hcv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html) using BLAST. Viral 
genotype call was based on the highest score and lowest e-value, using the NS5B 
sequence unless those results were negative or missing, in which case genotype was 
based on the 5NC region. 
 
2.4 IL28B Genotyping  
DNA was extracted from cryopreserved lymphocytes using a modified salt precipitation-
extraction method (Gentra Systems, Minneapolis, MN) or from granulocytes using silica 
membrane binding method using Qiagen DNA purification columns (Qiagen Inc, Valencia, 
CA). The NCI Core Genotyping Facility performed genotyping for IL28B rs12979860 using 
an optimized TaqMan assay (available at 
http://variantgps.nci.nih.gov/cgfseq/pages/snp500.do) 
 
2.5 Statistical Analyses   
All analyses were cross-sectional and based on a single study visit. We determined 
median HCV RNA levels (log10 copies/ml) overall and among subgroups. As neither log10 
HCV RNA nor alternative transformations of these data were normally distributed, non-
parametric statistical methods were the basis of the analysis. We used the Wilcoxon 
(Kruskal–Wallis) to compare the distribution of HCV RNA levels for variables in SAS 
PROC NPAR1WAY. To perform multivariate analysis we divided HCV RNA into quintiles 
and examined determinants of higher HCV RNA in unconditional ordinal logistic regression 
models that included age [or duration of injection drug use], gender, race/ethnicity, HBV 
infection, HIV-1 infection and HCV genotype (SAS PROC LOGISTIC). All analyses were 
performed using SAS version 9.1 (SAS Institute, Cary, NC).  
 
  
 
 
 
 
 
 
 
RESULTS
  RESULTS 
1. HIV RESULTS : 
 
1.1 POPULATION STUDY 
A total of 163 HIV-1 infected Progressors and 99 LTNP patients were included in this 
cohort. The characteristic of both are summarized in table 2 and 3 respectively. 
Table 2.  Characteristics of the HIV-Infected LTNP Patients 
N* 
 
 
 
58 
 
 
Age 
(yrs)  
 
 
49 (35-72) 
 
Sex (% women) 
 
 
20 (33.9) 
 Risk 
(%)  
 
   
 
 
Heteroexual 
 
11 (19) 
 
 
Homo BS TRSF** 
 
21 (36) 
 
 
Transfusion 
 
21 (36) 
 
 
homosex 
 
 
3 (4.5) 
 
 
other 
 
 
3 (4.5) 
 CD4 
ount  
 
 
780 (273-1837) 
 HIV 
RNA  
 
 
12524 (49-200,000) 
 HCV+ 
(%)  
 
 
34 (60) 
 HBsAg+ (%) 
 
 
12 (20) 
 
 
  
     * clinical data available only on 58 patients (out of 99) 
** Homo BS TRSF= Homosexual, Bisexual, Transfusion patients 
 
 
 
Table 3.  Characteristics of the HIV-Infected Progressor Patients at Their 
Entry in the Cohort   
N*       148   
 
Age (yrs) 
 
 
50.7 (33 - 75) 
 Sex (% women) 
 
41 (27.7) 
 Risk (%) 
 
   
 
 
Heteroexual 
 
50 (34,7) 
 
 
Homosexual 
 
23 (15,9) 
  PTD  50 (34,7) 
 
other  21 (14,5) 
 HCV+ 
(%) 
 
  63 
(42) 
 HBsAg+ (%)
  
3 (2) 
    
   * clinical data available only on 148 patients (out of 163)         
 
Clinical data were available for 58 patients out of 99 of the Progressors patients and 
148 out of 163 of the LTNP patients. Progressors patient was an extremely 
  RESULTS 
heterogeneous group, some patients had already started the antiretroviral therapy 
(not homogeneous treatment, i.e. TDF/FTC + ATV; ABC/3TC + ATV; fAMP) at the 
time of the beginning of the study whereas others were naïve to the therapy; the 
leading factor for this cohort was that the progression of the disease showed a CD4 
cell decay <500 cells/ml within 3 years from the date of HIV-1 positive diagnosis. 
Unfortunately, HIV viral load was only available in LNTP patients. 
 
1.2 GENETIC ASSOCIATION 
 
1.2.1 TLR9 SNPs association results 
Rs352139 TLR9 SNP amplification was possible in 162 samples in the progressors 
and 98 in the LTNP, whereas all the samples were genotyped for rs352140. 
Genotype and allele frequencies for the two SNPs were in Hardy-Weinberg 
equilibrium in both groups and are shown in table 4 and 5.  Rs352140 G allele was 
more frequent among LTNP (51% G allele vs. 49% A allele) and conversely A allele 
was more frequent in Progressors ( 57%  A allele vs. 43% G allele). 
 
 
 
 
 
 
 
LTNP PR Totale 
rs352140 AA 23 58 94 
    23.20% 35.60% 30.40% 
  AG 51 70 146 
    51.50% 42.90% 47.20% 
  GG 25 35 69 
    25.30% 21.50% 22.30% 
 
 
    
 
 
Table 4.  TRL9 genotype frequencies 
 
 
 
    
 
 
LTNP PR Totale 
rs352139 AA 24 29 61 
    24.50% 17.90% 19.90% 
  AG 48 74 146 
    49.00% 45.70% 47.70% 
  GG 26 59 99 
    26.50% 36.40% 32.40% 
 
 
    
  RESULTS 
 
 
 
 
 
 
Table 5. TRL9 SNPs allelic frequencies and HWE p values. 
  
          
rs352140 
LTNP 
AA AG GG 
 
rs352140 
Progressors 
AA AG GG 
 
Observed 23 51 25 
 
Observed 58 70 35 
 
Expected 23.76 49.48 25.8 
 
Expected 53.1 79.9 30.1 
 
          
Exact 
P=0.84 
P(A)= 0.49 
  
Exact 
P=0.11 
P(A)= 0.57 
  
 
P(G)= 0.51 
   
P(G)= 0.43 
  
          
rs352139 
LTNP 
AA AG GG  
rs352139 
Progressors 
AA AG GG 
 
Observed 24 48 26  Observed 29 74 59 
 
Expected 23.51 48.98 25.5 
 
Expected 26.9 78.2 56.9 
 
          
Exact 
P=0.841 
P(A)= 0.49 
  
Exact 
P=0.52 
P(A)= 0.41 
  
 
P(G)= 0.51 
   
P(G)= 0.59 
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 RESULTS 
The presence of the AA genotype in rs352140 was predominant in Progressors 
(rs352140: AG+GG: 76% LTNP vs. 64.4% progressors, AA: 23.2 % LTNP vs.35.6% 
Progressors, P = 0.025), (Table 6).  
 
 
 
 
 
 
 
 
 
 
 
No statistical association was found between the progressors group and the LTNP 
according to the frequencies of rs352139 TLR9 SNPs.  
No additional associations were found between TLR9 SNPs and viral load or CD4 
cell count progression. This association analysis were only performed among the 
LTNP group because and it was not possible perform it among progressors due to 
lack of availability of clinical data.  
 
1.2.2 IRF5 SNPs association results 
IRF5 SNPs amplification was possible in 163 samples in the progressors and 99 in 
the LTNP. Genotype and allele frequencies for the two SNPs were in Hardy-
Weinberg equilibrium (data showed below). Rs10954213/ rs11770589 GG genotype 
was less frequent among LTNP (Rs10954213: 11% LNTP vs. 26% PR; rs11770589: 
20,2% LTNP vs 22.8% PR) but no differences among those frequencies were 
statistically significant. 
 
Table 6. TLR9 rs352140 SNP association to HIV progression 
P=0.025 
      
rs352140 
 
PR 
 
LTNP 
    
AA 58 23 
   
  (35.6 %) (23.2 %) 
   
AG+GG 105 76 
   
 
(64.4%) (76.8 %) 
   
  163 99 
   
 
(62.2%) (37.8 %) 
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 RESULTS 
 
 
 
 
 
 
 
 
 
 
IRF5 SNPs allelic frequencies and HWE p values. 
         rs10954213 
LTNP 
AA AG GG 
 
rs10954213 
Progressors 
AA AG GG 
Observed 33 55 11 
 
Observed 63 73 26 
Expected 36.97 47.06 14.97 
 
Expected 61.11 76.77 24.11 
         
Exact 
P=0.137 
P(A)= 0.611 
  
Exact P=0.51 P(A)= 0.614 
 
 
P(G)= 0.389 
   
P(G)= 0.386 
 
         
rs11770589 
LTNP 
AA AG GG 
 
rs11770589 
Progressors 
AA AG GG 
Observed 24 55 20 
 
Observed 48 77 37 
Expected 26.79 49.42 22.79 
 
Expected 46.19 80.63 35.19 
         
Exact 
P=0.317 
P(A)= 0.52 
  
Exact 
P=0.635 
P(A)= 0.534 
 
 
P(G)= 0.48 
   
P(G)= 0.466 
 
         
1.2.3 Linkage Disequilibrium and Haplotype analyses 
  IRF5 genotype frequencies 
           
 
 rs10954213  
LTNP PR Totale 
 
 
AA 33 63 107 
     33,3% 38,9% 35,0% 
   AG 55 73 154 
    55,6% 45,1% 50,3% 
  GG 11 26 45 
    11,1% 16,0% 14,7% 
    
      
       
rs11770589 
 
LTNP PR Totale 
 
 
AA 24 48 78 
     24,2% 29,6% 25,5% 
   AG 55 77 158 
     55,6% 47,5% 51,6% 
   GG 20 37 70 
     20,2% 22,8% 22,9% 
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 RESULTS 
Linkage disequilibrium analysis confirmed the results of previous studies that a 
strong disequilibrium exists between the two SNPs of TLR9 and between the two 
SNPs of IRF5 with D’= 1, in both Progressors and LTNP.  
. 
To investigate their combined effect, given their close proximity, haplotype 
frequencies were estimated in both groups. However, no association was found in 
this analysis for none of the SNPs considered in this study (data not showed). 
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 RESULTS 
HCV results 
 
1.1 STUDY POPULATION:  
A total of 2092 UHS subjects had antibody to HCV. Among these, 2073 participants 
had sufficient plasma to be tested for HCV RNA of whom 1701 (82.1%) had 
detectable HCV RNA. Demographic and clinical features for the 1701 participants 
with HCV viremia were generally similar to those among all UHS subjects with HCV 
antibodies (Table A). Among those with detectable HCV RNA, the median age at 
enrollment was 46 years, the median age at which a drug was first injected was 18 
years and the median time from first use of injection drugs to enrollment was 26 
years. Most participants (72.4%) were men. Over half (56.0%) of the participants 
considered themselves African American, 34.0% white (non-Hispanic), 6.8% Latino 
(non- African American), 1.1% were Asian or Pacific Islanders and 2.2% were 
American Indian or Alaska natives. Infection with HIV-1 was present in 237 (13.9%) 
participants. As previously reported in this and other cohorts (7, 8, 12), chronic 
hepatitis B was less frequent and HIV-1 infection was more frequent among 
participants with chronic hepatitis C.  
 
1.2 PREDICTOR OF HCV RNA LEVELS 
1.2.1 All Subjects 
Among participants with detectable virus, the median HCV RNA level was 6.45 log10 
copies/ml [inter-quartile range, 5.97-6.89]. Median viral levels were progressively 
higher in each older age category, ranging from 6.15 log10 copies/ml among 
participants 18-29 years at enrollment to 6.59 log10 copies/ml among those >50 
years of age (p<0.0001; Table B). Duration of injection drug use is highly correlated 
with age at enrollment in UHS participants (r2=0.74) and there was also a strong 
trend toward higher HCV RNA levels with longer duration of drug use (<0.0001). 
HCV RNA levels were higher in men (6.52 log10 copies/ml) than women (6.29 log10 
copies/ml; p<0.0001). With regard to race and ethnicity, the highest levels were 
found in African American participants (6.49 log10 copies/ml), intermediate viral levels 
were found in white participants of non-Hispanic origin (6.35 log10 copies/ml) and 
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 RESULTS 
Latinos (6.39 log10 copies/ml), and the lowest levels were found in those who 
reported their ancestry as Asian, Pacific Islander, American Indian or an Alaska 
native (6.24 log10 copies/ml; Table B) with similar median HCV RNA levels among 
Asian/Pacific Islanders (6.24 log10 copies/ml; n=19) and American Indians/Alaska 
natives (6.18 log10 copies/ml; n=37). Regarding infection with other viruses, for 
subjects overall, those without antibody to HBV had lower HCV RNA levels than 
those with resolved or chronic HBV infection (Table 2). HCV RNA levels were higher 
in HIV-infected participants (6.73 log10 copies/ml) than in HIV-uninfected IDUs (6.40 
log10 copies/ml; p<0.0001). We also performed analyses stratified by HIV-1 infection 
status (Table B). Among the HIV-1-uninfected participants, the patterns of 
association were very similar to those seen among all viremic subjects except the 
HCV RNA level was consistently lower for each characteristic examined. Among the 
237 HIV-1-infected participants, differences by age, gender, and duration of drug use 
were blunted or absent, but differences between African American and white 
participants were preserved (0.01).   
Among the participants with detectable virus, 1669 had a specimen available for viral 
genotyping and 1524 (91.3%) of those subjects were successfully genotyped (Table 
C). Most participants were infected with an HCV-genotype 1 strain (1a, 69.0%; 1b, 
10.0%), but 9.3% were infected with a genotype 2 strain, 10.6% with a genotype 3 
strain and 1.1% with genotype 4a. The median HCV RNA level did not differ 
significantly between participants infected with 1a (6.50 log10 copies/ml) and those 
infected with 1b (6.63 log10 copies/ml; p=0.11). In comparison to participants who 
were infected with genotype 1 (median HCV RNA, 6.50 log10 copies/ml), HCV RNA 
was lower in those infected with genotype 3 (6.34 log10 copies/ml; p=0.0003) or 
genotype 4 (6.12 log10 copies/ml; p=0.03). We observed the lowest median HCV 
RNA level (5.64 log10 copies/ml) among participants who had detectable HCV RNA, 
but could not be genotyped.  
1.2.2 IL28B rs12979860 Genotype  
IL28B genotyping was performed for a subset of the participants with chronic 
hepatitis C (table D). Among 347 African American participants, we saw no 
differences in viral levels by IL28B genotype. Among 391 European American IDUs, 
those with the IL28-CC genotype had a higher median HCV RNA level (6.67 log10 
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 RESULTS 
copies/ml) than those with IL28–TT (6.12; p=0.01); the median HCV RNA level 
among European American participants with the IL28–CT genotype was 6.26 log10 
copies/ml. Among 88 participants of Hispanic ethnicity, median HCV RNA levels for 
those with the IL28-CC (6.63 log10 copies/ml) and IL28–TT (6.19 log10 copies/ml) 
genotypes were similar to those seen in European American participants, but this 
difference was not statistically significant among participants of Hispanic ethnicity, 
which is a much smaller group. 
1.3 MULTIVARIATE ANALYSES  
Results from the multivariable ordinal logistic regression analysis (Table E) 
confirmed the unadjusted findings. HCV RNA levels were higher for older 
participants, men and those infected with HIV-1. Compared to African Americans, 
HCV RNA levels were lower in all other ancestry groups, although this difference did 
not approach statistical significance for the comparison with Latinos (p =0.44). 
Regarding viral genotype, compared to those infected with genotype 1, participants 
infected with genotype 2 had higher HCV RNA (p=0.01).  The IL28B-CC genotype 
was associated with higher HCV RNA (p = 0.001). A model that substituted duration 
of drug use for age produced similar results. In view of the findings in Table D, we 
also conducted a multivariate analysis that including a term for an interaction 
between IL28B  rs12979860 genotype and race/ethnicity, but this interaction was not 
statistically significant (p>0.10). but levels in those with the heterozygous genotype 
were not significantly higher than those with the TT genotype (p = 0.17). A model 
that substituted duration of drug use for age produced similar results.  
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DISCUSSION 
Discussion (HIV) 
 
There is increasing evidence for a role for TLRs in HIV-1 pathogenesis. In the 
present study, we found that the minor allele A of rs352140 TLR9 SNPs was more 
frequent among rapid progressors than among LTNP patients. While our 
observations support the hypothesis of a role for TLRs in HIV-1 infection, the precise 
mechanisms of the interaction between HIV-1 and innate immune cells remain poorly 
understood. During reverse transcription, HIV-1 produces double-stranded DNA 
containing CpG motifs; these are transferred from the cytoplasm to the nucleus and 
integrated in the host cell genome. Since TLR9 is exclusively located in the 
endosomal compartment, debris phagocytosed from HIV-1-infected cells containing 
sufficient amounts of proviral DNA may activate macrophages through TLR9. 
In addition, TLR9 as well as other TLRs, may be activated by pathogens that are 
frequently associated with HIV-1 infection (e.g., mycobacteria, cytomegalovirus, 
herpes simplex virus and hepatitis C virus), thereby inducing the production of 
inflammatory cytokines and modulating viral replication. TLRs activation results in 
the production of inflammatory cytokines that can enhance viral replication. HIV-1 
replication is directly dependent on NF-kB, a critical TLR-induced transcription factor 
that promotes activation of the HIV-1 long terminal repeat. This might be of 
importance in the mechanism underlying the increased HIV-1 replication and disease 
progression associated with concomitant and opportunistic infections. This study 
suggests an important role for TLR9 and serves to generate several hypotheses for 
the pathogenesis of HIV-1 infection.  
Recent studies have analyzed the role of SNPs in the clinical context of HIV 
infection. Ferweda et al. reported a potential association between the TLR4 
Asp299Gly SNP and a higher susceptibility to develop active tuberculosis in HIV-
infected patients in Tanzania.  Bochud’s study reported association between CD4 
cell depletion and the rs352140 A/G SNP in the TLR9 gene among rapid 
progressors, failing to find an association with HIV viral load. Ricci’s group focused 
their research on the role of rs352139 and rs352140 TLR9 polymorphisms in mother 
to child transmission of HIV-1 and they showed no association of the two 
polymorphisms with rapid progression; however, the rs352140 GG and AA haplotype 
were associated with higher of rapid progression compare to the prevalent AG 
haplotype. Freguja’s group recently reported that TLR9 rs352139 AA associated with 
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better prognosis and was significantly associated with a slow disease progression of 
the disease and conversely, that TLR9 rs352140 AG genotype associated with 
Rapid Progression in HIV-infected children.  
This study show lack of an association of TLR9 polymorphisms with the rapid CD4 
cell decline or HIV viral load as it has been found in the studies mentioned above. 
The role of rs352139 and rs352140 TLR9 SNPs differences between LTNP and 
Progressors patient has been analyzed. However, this study was limited by several 
factors. The cohort of Progressors was extremely heterogeneous, some patients had 
already started the antiretroviral therapy at the time of the beginning of the study 
whereas others were naïve to the therapy; the leading factor for this cohort was that 
the progression of the disease showed a CD4 cell decay <500 cells/ml within 3 years 
from the date of HIV-1 positive diagnosis. Furthermore, in our study, HIV viral load 
was only available in LNTP patients, and therefore our analyses were restricted in 
this variable. Finally, genetic associations can be biased by population stratification. 
Our cohort of LNTP was not limited to the analyses to one single homogeneous 
population and this factor could have played a major role on the meaning and lack of 
an association with CD4 count and HIV viral load. 
 
In conclusion, specific genotypes and haplotypes in the TLR9 gene may affect the 
functional ability of their encoded proteins to modulate innate immunity and immune 
activation, thus contributing to the variability of clinical outcome in HIV-1 infected 
patients. 
 
 
 
DISCUSSION (HCV) 
In this large multi-racial cohort of IDUs with chronic hepatitis C infection, HCV RNA 
levels were independently associated with six factors: age, gender, racial ancestry, 
HIV-1 infection, HCV genotype and host IL28B genotype.  
HCV RNA levels tended to be higher with older age and longer duration of drug 
injection, variables which are highly correlated in this study. The average time since 
initiation of drug use in these IDUs is 19 years and, at least until recently, most IDUs 
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who enrolled in UHS became infected with HCV relatively soon after initiating drug 
injection. We believe, therefore, that reported years of injection drug practices is a 
reasonable proxy for the time since initial infection with HCV. Our data suggest that 
HCV RNA levels may increase ~2.4% (0.15 “logs”) per year or ~25% per decade. 
Consistent findings were previously reported in another cross-sectional study of 
IDUs, but results from longitudinal studies of HCV RNA are mixed. The study with 
the longest follow-up period (median, 9.2 years) found that HCV RNA levels 
increased over time, but studies based on shorter follow-up periods (average 1-5 
years) did not. These shorter studies may have lacked the statistical power to 
exclude a 2.4% annual increase (13% increase in 5 years), therefore, those results 
are not necessarily inconsistent with our own. Our findings suggest that HCV may 
propagate more efficiently over time. The explanation for this observation is beyond 
the scope of this investigation, but we speculate it could reflect selection of HCV 
variants with high replicative efficiency or host loss of immunological control of HCV 
over time, perhaps due to immune senescence. Higher HCV RNA levels are 
associated with lower rates of sustained virological response after treatment with 
pegylated interferon and ribavirin, therefore, evidence that HCV RNA levels increase 
over time may weigh for earlier treatment of chronic HCV infection.  
In the absence of HIV-1 infection, HCV-RNA levels tended to be lower for women in 
this study compared to men and this difference remained even after potential 
confounding variables were considered. Among the 237 HIV-infected UHS 
participants, however, median HCV RNA levels were similar in women and men. In 
the ALIVE study of IDUs, Thomas et al saw somewhat lower HCV RNA levels in 
women compared to men among HIV-uninfected subjects, although that association 
was not statically significant in a multivariate analysis. As in our study, HCV RNA 
levels did not differ by gender among the HIV-infected ALIVE participants. Among 
HCV-infected Alaska Natives, women had much lower levels of HCV RNA than men.  
Comparing HCV RNA by racial ancestry, UHS participants who were African 
American tended to have higher levels than participants of European or Asian 
ancestry, even after we considered other factors, including IL28B genotype. Few 
previous studies have been able to make such comparisons. In ALIVE, no difference 
in HCV RNA levels was seen between African American subjects and those of other 
races, however, only 40 non-African American subjects were included in that 
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analysis. Among patients enrolled in treatment trials for chronic hepatitis C, pre-
treatment HCV RNA levels did not different between African American and European 
American subjects in either the VirahepC  or IDEAL studies.  
HCV-RNA levels were considerably higher among UHS participants who were 
infected with HIV-1 (6.73 log10 copies/ml) compared to those who were not (6.40 
log10 copies/ml), which is consistent with the results from a number of previous 
studies. In our study, we were able to control for a fuller range of potential 
confounding, but this association remained strong even when these factors were 
considered.  
Among the subjects for whom we could determine viral genotype, almost 80% were 
infected with HCV genotype 1A or 1B; the median HCV RNA level in this group was 
6.51 log10 copies/ml. UHS participants who were infected with HCV genotype 2 had 
higher HCV RNA levels (median, 6.69 log10) than those infected with genotype 1, 
although this difference reached statistical significance only when other factors were 
considered in the analysis. We observed lower viral levels in participants who were 
infected with genotype 3 (median, 6.35 log10; n=162) or genotype 4 (median, 6.12 
log10; n=17), but those findings were not statistically significant in the multivariate 
analysis, perhaps due to insufficient statistical power. Consistent with our findings, 
an earlier report of Swiss blood transfusion recipients co-infected with HIV-1 showed 
the highest HCV RNA levels in patients with genotype 2, and the lowest levels in 
patients with genotype 4. In a multi-national study (predominantly IDUs), HCV RNA 
levels were lowest among subjects infected with genotypes 3 or 4, and similar 
among those with genotypes 1 and 2, although relatively few subjects with genotype 
2 were included in this analysis. Among Alaska Natives, the lowest HCV RNA levels 
were found in persons infected with HCV genotypes 3a and the highest in those 
infected with genotype 2b.  There were no patients with genotype 4 in the analysis.  
Several variables that we found to be associated with higher HCV RNA among UHS 
participants (older age, male gender, African ancestry and HIV infection) were 
previously associated with failure to spontaneously clear HCV infection in this cohort, 
as well as in other studies. An exception to this pattern is the IL28B-CC genotype, 
which is associated with increased spontaneous HCV clearance in UHS (Shebl, 
submitted) (and other studies ), but also higher HCV RNA (among the European 
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American participants and UHS subjects overall). Paradoxically, the rs12979860-CC 
genotype, which is associated with better response to pegylated interferon /ribavirin 
therapy and a higher frequency of spontaneous HCV clearance, has been 
associated with higher HCV RNA levels in those with chronic hepatitis C. Some prior 
reports found higher baseline HCV RNA to be associated with the otherwise 
favorable IL28B genotype, but other studies did not. Comparing participants by racial 
ancestry, African American UHS participants had the highest HCV RNA levels 
despite having the lowest frequency of the IL28B –CC genotype. Furthermore, we 
did not see the association between higher HCV RNA and IL28B –CC among the 
African American participants. It is possible, therefore, that there are additional 
genetic factors that lead to poorer viral control among persons of African ancestry.  
Our study has a number of strengths. Because UHS is a multi-racial cohort of street-
recruited IDUs we could compare HCV RNA across ancestral groups without the 
potential biases caused by markedly differing sources of HCV infection or 
socioeconomic status. Few, if any, of the UHS participants had been treated for HCV 
infection, therefore, the HCV RNA values among these subjects were not subject to 
selection by previous HCV treatment. The relatively large size of the cohort provided 
good statistical power for many comparisons, although our power was low for certain 
variable categories, including Hispanic or Asian ancestry and viral genotypes 3 or 4. 
The limitations of our study should be considered as well. The cross-sectional design 
did not allow us to determine the timing of HCV, HBV and HIV infections among the 
participants and we also could not differentiate the effect of duration of infection (as 
estimated by number of years of drug injection) from the effect of age because these 
factors are highly correlated. As mentioned above, we could not determine whether 
the relationship between duration of infection might represent super-infection, 
immune senescence or some other factor that varies with time or age.  
We performed viral genotyping by direct sequencing, the ‘gold standard’ technique 
for discriminating HCV types and subtypes. This genotyping was based on the NS5B 
region, which tends to produce more accurate results than the 5’NC region. An 
important concern in this analysis is whether methodological differences may 
account for the discrepancies in HCV RNA levels between different genotypes. We 
used a third generation bDNA assay with an analytic sensitivity of 2.5x103 copies/ml 
to measure viral levels. This method amplifies signal rather than target, which is the 
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basis for classical reverse transcription polymerase chain reaction (PCR) and 
transcription-mediated amplification assays. First-generation bDNA assays 
underestimated levels of HCV genotype 2 and 3, but third-generation bDNA tests are 
accurate, reproducible and well calibrated to the World Health Organization HCV 
RNA standard. In support of our findings, a previous report of an association 
between HCV genotype 4 infection and lower HCV RNA levels was based on 
measurement by PCR and determined that the results were not influenced by viral 
genotype-specific amplification bias.  
In conclusion, the level of HCV viremia, an important predictor of response to HCV 
treatment, is itself influenced by a wide range of demographic, viral and host genetic 
factors. A better understanding of the determinants of HCV viremia could lead to 
improved treatment of patients with chronic hepatitis C. 
 71 
 
Table A. Characteristics of HCV-infected injection drug users, San Francisco Bay area, 1998–2000. 
  HCV antibody 
(n=2092) 
HCV viremia 
(n=1701) 
Viral genotype 
(n=1524) 
IL28B genotype 
(n=882) 
Characteristic   Median IQR a Median IQR Median IQR Median IQR 
Age at enrollment   45 40-50 46 40-50 46 40-50 44  39-49  
          
Years of injection drug use   25 17-31 26 18-32 26 18-32 25  18-31  
          
Age at first injection drug use   18 16-24 18 16-24 18 16-24 18  16-22  
         
  No. % No. % No. % No. % 
Gender b         
   Male  1461 70.9 1222 72.4 1104 73.1 615 69.7 
   Female  600 29.1 465 27.6 407 26.9 267 30.3 
          
Race           
   White  759 36.3 577 33.9 522 34.3 391 44.3 
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   African American  1078 51.5 951 55.9 861 56.5 347 39.3 
   Latino   167 8.0 115 6.8 92 6.0 88 10.0 
   Asian or Pacific Islander                           28 1.3 19 1.1 15 1.0 18 2.0 
   American Indian                           58 2.8 37 2.2 32 2.1 36 4.1 
   Other  2 0.1 2 0.1 2 0.1 2 0.2 
          
Hepatitis B virus infection          
   Acute   18 0.9 7 0.4 7 0.5 5 0.6 
   Chronic   53 2.5 29 1.7 26 1.7 28 3.2 
   Resolved  1641 78.4 1348 79.2 1197 78.5 680 77.1 
   Vaccinated  78 3.7 70 4.1 65 4.3 38 4.3 
   Uninfected and unvaccinated  302 14.4 247 14.5 229 15.0 131 14.9 
          
HIV-1 infection  262 12.5 237 13.9 211 13.8 107 12.1 
 
a. IQR: inter-quartile range (25th percentile-75th percentile); b. Missing data: gender, 31 
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Table B. Median HCV RNA levels (log10 copies/ml) among injection drug users with detectable HCV 
RNAa, by selected demographic and viral variables - San Francisco Bay area, 1998-2000.  
 
  All Subjects HIV-1 Uninfected Subjects HIV-1 Infected Subjects 
Characteristic No. HCV 
RNA 
p-value No. HCV 
RNA 
p-value No. HCV 
RNA 
p-
value 
Overall 1701 6.45  1461 6.40  237 6.73  
Age          
   18-29 years 84 6.15  76 6.11  8 6.32  
   30-39 years 303 6.29  243 6.25  60 6.74  
   40-49 years 845 6.47  724 6.43  119 6.73  
    >50 years 469 6.59  418 6.56  50 6.79  
   <.0001   <.0001   0.15 
Years injection 
drug use  
         
   0-9 years 176 6.08  158 6.04  18 6.42  
   10-19 years 316 6.29  265 6.21  51 6.75  
   20-29 years 602 6.47  504 6.44  96 6.62  
   ≥ 30 years 573 6.61  508 6.59  64 6.84  
   <.0001   <.0001   0.08 
Gender          
   Male  1222 6.52  1053 6.49  167 6.71  
   Female  465 6.29  397 6.21  67 6.79  
   <.0001   <.0001   0.47 
Race          
   African 
American 
951 6.49  806 6.45  144 6.78  
   White 577 6.35  500 6.34  76 6.56  
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   Latino 115 6.39  106 6.37  9 6.58  
  Asian or 
American Indian 
56 6.24  47 6.23  8 6.49  
   <.0001   0.002   0.04 
HBV infection           
Resolved 1348 6.48  1143 6.44  203 6.73  
  Chronic 29 6.64  22 6.22  6 6.96  
   0.57   0.67   0.40 
   Uninfected 247 6.30  230 6.25  17 6.77  
   0.0001   0.0005   0.45 
a. Subjects with undetectable HCV RNA were excluded 
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Table C. Median HCV RNA levels (log10 copies/ml) among injection drug users with detectable HCV RNAa, by HCV genotype - San Francisco Bay area, 1998-
2000.  
 
HCV  
Genotype* Frequency Percent 
Percent 
(excludes NR) Median p-value 
Median p-value 
1A 1057 63.07 69.08 6.50 
6.51  1B 152 9.07 9.93 6.63 0.11 
2A 15 0.89 0.98 6.71 0.92 
6.69 0.31 2B 127 7.58 8.30 6.69 0.19 
3A 160 9.55 10.46 6.35 0.001 
6.35 0.0004 3B 2 0.12 0.13 6.08 0.37 
4A 17 1.01 1.11 6.12 0.04 6.12 0.03 
NR 146 8.71  5.64  <0001 5.64 <0.0001 
Total 1676       
 
*Viral genotype is based on NS5B sequence 
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Table D: HCV RNA levels load among injection drug users with chronic HCV, by IL28B rs12979860genotype- San Francisco Bay area, 1998-2000. 
 
 
 
  
African American 
(n=347) 
European American 
(n=391) 
Hispanic 
(n=88) 
Asian/American Indian 
(n=54) 
Genotype Number RNA 
Median 
p-value Number RNA 
Median 
p-value Number RNA 
Median 
p-value Number RNA 
Median 
p-value 
TT 123 6.44 
 
41 6.12 
 
10 6.19 
 
7 6.28 
 TC 177 6.51 0.33 185 6.26 0.34 48 6.53 0.21 20 6.27 0.46 
CC 47 6.48 0.68 165 6.67 0.01 30 6.63 0.15 27 5.89 1.00 
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Table E. Multivariate ordinal logistic regression analysis of HCV RNA levels (log10 copies/ml) among 
874 injection drug users with chronic hepatitis C, San Francisco Bay area, 1998-2000. The analysis is 
limited to subjects with results for IL28B rs12979860 genotype.  
 
 Subjects with IL28B Genotype 
(n=874) 
Characteristic OR 95% CI p-value 
Age 1.28 1.10 - 1.50 0.001 
    
Female Gender 0.73 0.56 - 0.95 0.02 
    
Race    
   White 0.70 0.52 - 0.94 0.02 
   Latino 0.84 0.54 - 1.31 0.44 
  Asian or  
  American Indian            0.39 0.23 - 0.69 0.001 
    
Chronic HBV 1.06 0.53 - 2.14 0.86 
    
 HIV-1  1.95 1.34 - 2.83 0.0004 
    
HCV Genotype*    
1A/1B    
2A/2B 1.78 1.14 - 2.77 0.01 
3A/3B 0.80 0.55 - 1.17 0.25 
4A 0.37 0.12 - 1.15 0.09 
NR 0.17 0.11 - 0.28 <.0001 
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  IL28B genotype    
TT    
CT 1.10 0.80-1.51 .17 
CC 1.69 1.17-2.44 0.001 
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Supplemental table 1. Multivariate ordinal logistic regression analysis of HCV RNA levels (log10 
copies/ml) among injection drug users who were chronically infected with HCV, San Francisco Bay 
area, 1998-2000 - all subjects and the subset of subjects with IL28B rs12979860 genotype results. 
 
 All Subjects 
(n=1,650) 
Subjects with IL28B Genotype 
(n=874) 
Characteristic OR 95% CI p-value OR 95% CI p-value 
Age 1.33 1.18 - 1.49 <.0001 1.28 1.10 - 1.50 0.001 
       
Female Gender 0.64 0.53 - 0.78 <.0001 0.73 0.56 - 0.95 0.02 
       
Race       
   White 0.86 0.70 - 1.06 0.16 0.70 0.52 - 0.94 0.02 
   Latino 0.90 0.63 - 1.28 0.55 0.84 0.54 - 1.31 0.44 
  Asian or  
  American Indian            0.48 0.29 - 0.80 0.01 0.39 0.23 - 0.69 0.001 
       
Chronic HBV 1.25 0.64 - 2.46 0.51 1.06 0.53 - 2.14 0.86 
       
 HIV-1  2.13 1.65 - 2.75 <.0001 1.95 1.34 - 2.83 0.0004 
       
HCV Genotype*       
1A/1B       
2A/2B 1.30 0.94 - 1.79 0.11 1.78 1.14 - 2.77 0.01 
3A/3B 0.68 0.50 - 0.93 0.02 0.80 0.55 - 1.17 0.25 
4A 0.50 0.20 - 1.20 0.12 0.37 0.12 - 1.15 0.09 
NR 0.20 0.15 - 0.28 <.0001 0.17 0.11 - 0.28 <.0001 
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  IL28B genotype       
TT       
CT    1.10 0.80-1.51 .17 
CC    1.69 1.17-2.44 0.001 
Supplemental table 2. Unadjusted  and multivariate ordinal logistic regression analysis of HCV RNA levels 
(log10 copies/ml) among 874 injection drug users with IL28B rs12979860 genotype results who were 
chronically infected with HCVa, San Francisco Bay area, 1998-2000 
 Unadjusted 
 
Adjusted  
(Without IL28B 
Genotype) 
Adjusted  
(With  
IL28B Genotype) 
Characteristic OR 95% CI p-
value 
OR 95% CI p-
value 
OR 95% CI p-value 
Age 
1.28 
1.11 - 
1.47 0.001 1.27 
1.09 - 
1.48 0.002 1.28 1.10 - 1.50 0.001 
          
Female Gender 
0.66 
0.51 - 
0.85 0.002 0.73 
0.56 - 
0.94 0.02 0.73 0.56 - 0.95 0.02 
          
Race          
   White 
0.76 
0.59 - 
0.98 0.04 0.78 
0.58 - 
1.04 0.09 0.70 0.52 - 0.94 0.02 
   Latino 
0.83 
0.55 - 
1.26 0.39 0.91 
0.59 - 
1.41 0.68 0.84 0.54 - 1.31 0.44 
  Asian or  
  American 
Indian            0.47 
0.28 - 
0.80 0.006 0.46 
0.27 - 
0.80 0.01 0.39 0.23 - 0.69 0.001 
          
Chronic HBV 
1.04 
0.53 - 
2.05 0.91 1.17 
0.59 - 
2.35 0.65 1.06 0.53 - 2.14 0.86 
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 HIV-1  
1.73 
1.20 - 
2.49 0.003 1.95 
1.34 - 
2.82 0.0004 1.95 1.34 - 2.83 0.0004 
          
HCV Genotype*          
1A/1B          
2A/2B 1.64 
1.07 - 
2.51 0.02 1.90 
1.22 - 
2.95 0.004 1.78 1.14 - 2.77 0.01 
3A/3B 0.77 
0.54 - 
1.10 0.15 0.87 
0.60 - 
1.27 0.48 0.80 0.55 - 1.17 0.25 
4A 0.48 
0.16 - 
1.48 0.20 0.43 
0.14 - 
1.33 0.14 0.37 0.12 - 1.15 0.09 
NR 0.17 
0.11 - 
0.28 <.0001 0.18 
0.11 - 
0.30 <.0001 0.17 0.11 - 0.28 <.0001 
          
  IL28B genotype          
TT          
CT 
1.05 
0.77 - 
1.43 0.45    1.10 0.80-1.51 0.17 
CC 
1.33 
0.95 - 
1.85 0.05    1.69 1.17-2.44 0.001 
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